Publications
2024
Common Lymphoid Progenitors and B Cell Subpopulations in the Bone Marrow Are Predictive of Treatment-Free Remission in Chronic Myeloid Leukemia
Patterson, S. D., Nosratzadeh, I., Young, R., Hair, A., Cassels, J., Clark, R. E., . . . Copland, M. (2024). Common Lymphoid Progenitors and B Cell Subpopulations in the Bone Marrow Are Predictive of Treatment-Free Remission in Chronic Myeloid Leukemia. Blood, 144(Supplement 1), 994. doi:10.1182/blood-2024-204864
Predicting treatment-free remission outcomes in Chronic Myeloid Leukemia patients using an integrated model of tumor-immune dynamics
2023
P503: A RANDOMISED TRIAL OF MOLECULAR MONITORING VERSUS STANDARD CLINICAL CARE IN YOUNGER ADULTS WITH ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE UK NCRI AML17 AND AML19 STUDIES
Potter, N., Jovanovic, J., Ivey, A., Thomas, A., Wilhelm-Benartzi, C., Gilkes, A., . . . Dillon, R. (n.d.). P503: A RANDOMISED TRIAL OF MOLECULAR MONITORING VERSUS STANDARD CLINICAL CARE IN YOUNGER ADULTS WITH ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE UK NCRI AML17 AND AML19 STUDIES. HemaSphere, 7(S3), e345570d. doi:10.1097/01.hs9.0000968920.34557.0d
Cardiovascular risk in chronic myeloid leukaemia: A multidisciplinary consensus on screening and management
Milojkovic, D., Lyon, A. R., Mehta, P., Dimitriadou, E., Choudhuri, S., Manisty, C., . . . Clark, R. E. (2023). Cardiovascular risk in chronic myeloid leukaemia: A multidisciplinary consensus on screening and management. EUROPEAN JOURNAL OF HAEMATOLOGY, 111(2), 201-210. doi:10.1111/ejh.13983
Generic imatinib: Data from the UK National Registry for chronic myeloid leukaemia patients
Nesr, G., Braithwaite, B., Mathew, P., Hashmi, M., Claudiani, S., Milojkovic, D., . . . Clark, R. E. (2023). Generic imatinib: Data from the UK National Registry for chronic myeloid leukaemia patients. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 201 (pp. 92-93). Retrieved from https://www.webofscience.com/
2022
Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation
Karg, E., Baldow, C., Zerjatke, T., Clark, R. E., Roeder, I., Fassoni, A. C., & Glauche, I. (2022). Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation. FRONTIERS IN ONCOLOGY, 12. doi:10.3389/fonc.2022.1028871
Digital Droplet (dd) Polymerase Chain Reaction (PCR) Assays Offer Limited Advantages over Conventional Reverse-Transcriptase Quantitative PCR (RT-qPCR) for the Prediction of Molecular Recurrence after Treatment Discontinuation in Chronic Myeloid Leukemia (CML): Results from the Destiny Study
Dominy, K., Salmon, M., Szydlo, R., Hayden, C., White, H. E., Alikian, M., . . . Apperley, J. F. (2022). Digital Droplet (dd) Polymerase Chain Reaction (PCR) Assays Offer Limited Advantages over Conventional Reverse-Transcriptase Quantitative PCR (RT-qPCR) for the Prediction of Molecular Recurrence after Treatment Discontinuation in Chronic Myeloid Leukemia (CML): Results from the Destiny Study. In BLOOD Vol. 140 (pp. 9631-9632). doi:10.1182/blood-2022-170375
Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation
A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands
Claudiani, S., Janssen, J. J. W. M., Byrne, J., Smith, G., Blijlevens, N., Raghavan, M., . . . Apperley, J. F. (2022). A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands. EUROPEAN JOURNAL OF HAEMATOLOGY, 109(1), 90-99. doi:10.1111/ejh.13775
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial
Brummendorf, T. H., Cortes, J. E., Milojkovic, D., Gambacorti-Passerini, C., Clark, R. E., le Coutre, P., . . . Deininger, M. W. (2022). Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. In LEUKEMIA Vol. 36 (pp. 1825-1833). doi:10.1038/s41375-022-01589-y
Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial
Russell, N. H., Hills, R. K., Thomas, A., Thomas, I., Kjeldsen, L., Dennis, M., . . . Burnett, A. K. (2022). Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial. HAEMATOLOGICA, 107(7), 1518-1527. doi:10.3324/haematol.2021.279010
Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation
P691: MODELLING OF IMMUNE RESPONSE IN CHRONIC MYELOID LEUKEMIA PATIENTS SUGGESTS POTENTIAL FOR TREATMENT REDUCTION PRIOR TO CESSATION
Karg, E., Baldow, C., Zerjatke, T., Clark, R. E., Roeder, I., Fassoni, A. C., & Glauche, I. (n.d.). P691: MODELLING OF IMMUNE RESPONSE IN CHRONIC MYELOID LEUKEMIA PATIENTS SUGGESTS POTENTIAL FOR TREATMENT REDUCTION PRIOR TO CESSATION. HemaSphere, 6, 586-587. doi:10.1097/01.hs9.0000845648.71966.87
P713: REAL-WORLD MANAGEMENT OF PATIENTS WITH CHRONIC MYELOID LEUKAEMIA (CML): FIRST ANALYSIS FROM THE UK NATIONAL REGISTRY FOR CML
Nesr, G., Szydlo, R., Braithwaite, B., Frackelton, S., Mathew, P., Hashmi, M., . . . Clark, R. E. (n.d.). P713: REAL-WORLD MANAGEMENT OF PATIENTS WITH CHRONIC MYELOID LEUKAEMIA (CML): FIRST ANALYSIS FROM THE UK NATIONAL REGISTRY FOR CML. HemaSphere, 6, 608-609. doi:10.1097/01.hs9.0000845736.31547.3f
A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial
Russell, N. H., Hills, R. K., Kjeldsen, L., Clark, R. E., Ali, S., Cahalin, P., . . . Burnett, A. K. (2022). A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial. BRITISH JOURNAL OF HAEMATOLOGY. doi:10.1111/bjh.18195
The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia
Gallipoli, P., Clark, R. E., Byrne, J., Apperley, J. F., Milojkovic, D., Foroni, L., . . . O'Brien, S. (2022). The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 196(6), E55-E57. doi:10.1111/bjh.17961
Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial
Copland, M., Slade, D., McIlroy, G., Horne, G., Byrne, J. L., Rothwell, K., . . . Yap, C. (2022). Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial. LANCET HAEMATOLOGY, 9(2), E121-E132. doi:10.1016/S2352-3026(21)00370-7
2021
Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients
Dennis, M., Thomas, I. F., Ariti, C., Upton, L., Burnett, A. K., Gilkes, A., . . . Grp, U. K. N. C. R. I. A. M. L. W. (2021). Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients. BLOOD ADVANCES, 5(24), 5621-5625. doi:10.1182/bloodadvances.2021005038
Ponatinib in Combination with FLAG-IDA Chemotherapy for Blast -Phase Chronic Myeloid Leukemia: Final Results of the Seamless Phase I/II Dose -Finding UK Trials Acceleration Programme (TAP) Matchpoint Trial
Copland, M., Slade, D., McIlroy, G., Horne, G., Byrn, J., Rothwell, K., . . . Yap, C. (2021). Ponatinib in Combination with FLAG-IDA Chemotherapy for Blast -Phase Chronic Myeloid Leukemia: Final Results of the Seamless Phase I/II Dose -Finding UK Trials Acceleration Programme (TAP) Matchpoint Trial. In BLOOD Vol. 138. doi:10.1182/blood-2021-147972
A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial
Dennis, M., Burnett, A., Hills, R., Thomas, I., Ariti, C., Severinsen, M. T., . . . Russell, N. (2021). A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial. BRITISH JOURNAL OF HAEMATOLOGY, 194(2), 298-308. doi:10.1111/bjh.17501
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (vol 35, 20-LEU-1554R, 2021)
Kantarjian, H. M., Hughes, T. P., Larson, R. A., Kim, D. -W., Issaragrisil, S., le Coutre, P., . . . Hochhaus, A. (2021). Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (vol 35, 20-LEU-1554R, 2021). LEUKEMIA, 35(7), 2142-2143. doi:10.1038/s41375-021-01306-1
Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias
Makela, E., Pavic, K., Varila, T., Salmenniemi, U., Loyttyniemi, E., Nagelli, S. G., . . . Westermarck, J. (2021). Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias. CLINICAL CANCER RESEARCH, 27(10), 2848-2860. doi:10.1158/1078-0432.CCR-20-3679
Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia
Clark, R. E., Basabrain, A. A., Austin, G. M., Holcroft, A. K., Loaiza, S., Apperley, J. F., . . . Lucas, C. M. (2021). Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia. CANCERS, 13(9). doi:10.3390/cancers13092155
Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression
Clark, R. E., Apperley, J. F., Copland, M., & Cicconi, S. (2021). Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression. BLOOD ADVANCES, 5(4), 1102-1109. doi:10.1182/bloodadvances.2020003570
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis
Kantarjian, H. M., Hughes, T. P., Larson, R. A., Kim, D. -W., Issaragrisil, S., le Coutre, P., . . . Hochhaus, A. (n.d.). Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. doi:10.1038/s41375-020-01111-2
Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study
Milojkovic, D., Cross, N. C. P., Ali, S., Byrne, J., Campbell, G., Dignan, F. L., . . . Mead, A. J. (2021). Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study. BRITISH JOURNAL OF HAEMATOLOGY, 192(1), 62-74. doi:10.1111/bjh.16733
2020
Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses.
Burnett, A. K., Russell, N. H., Hills, R. K., Knapper, S., Freeman, S., Huntly, B., . . . Spearing, R. (2020). Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2001170. doi:10.1200/jco.20.01170
Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review
Cortes, J. E., Candoni, A., Clark, R. E., Leber, B., Montesinos, P., Vyas, P., . . . Heuser, M. (2020). Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review. Leukemia and Lymphoma, 61(14), 3287-3305. doi:10.1080/10428194.2020.1817445
Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial
Brümmendorf, T. H., Cortes, J. E., Milojkovic, D., Gambacorti-Passerini, C., Clark, R. E., le Coutre, P. D., . . . Deininger, M. W. (2020). Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial. Blood, 136(Supplement 1), 41-42. doi:10.1182/blood-2020-137393
The chronic myeloid leukaemia story in the United Kingdom since 1960
Clark, R. E. (2020). The chronic myeloid leukaemia story in the United Kingdom since 1960. BRITISH JOURNAL OF HAEMATOLOGY, 191(4), 521-526. doi:10.1111/bjh.17149
Discovery of NOvel CIP2A VAriant (NOCIVA) and its clinical relevance in myeloid leukemias
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia
Pfirrmann, M., Clark, R. E., Prejzner, W., Lauseker, M., Baccarani, M., Saussele, S., . . . Hoffmann, V. S. (2020). The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. LEUKEMIA, 34(8), 2138-2149. doi:10.1038/s41375-020-0931-9
Another set of guidelines for chronic myeloid leukaemia
Clark, R. E. (2020). Another set of guidelines for chronic myeloid leukaemia. British Journal of Haematology. doi:10.1111/bjh.16970
A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease
Horne, G. A., Stobo, J., Kelly, C., Mukhopadhyay, A., Latif, A. L., Dixon-Hughes, J., . . . Copland, M. (2020). A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. LEUKEMIA, 34(7), 1775-1786. doi:10.1038/s41375-019-0700-9
Correction: CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.
Kinstrie, R., Horne, G. A., Morrison, H., Irvine, D., Munje, C., Castañeda, E. G., . . . Copland, M. (2020). Correction: CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.. Leukemia, 34(7), 1975. doi:10.1038/s41375-020-0721-4
CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy
Kinstrie, R., Horne, G. A., Morrison, H., Irvine, D., Munje, C., Castaneda, E. G., . . . Copland, M. (2020). CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. LEUKEMIA, 34(6), 1613-1625. doi:10.1038/s41375-019-0684-5
Serotonin re-uptake transporter gene polymorphisms are associated with imatinib-induced diarrhoea in chronic myeloid leukaemia patients.
Davies, A., Rodriguez-Vicente, A. E., Austin, G., Loaiza, S., Foroni, L., Clark, R. E., & Pirmohamed, M. (2020). Serotonin re-uptake transporter gene polymorphisms are associated with imatinib-induced diarrhoea in chronic myeloid leukaemia patients.. Scientific reports, 10(1). doi:10.1038/s41598-020-65350-0
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., . . . Hehlmann, R. (2020). European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. LEUKEMIA, 34(4), 966-984. doi:10.1038/s41375-020-0776-2
Molecular dynamics during reduction of TKI dose reliably identify molecular recurrence after treatment cessation in CML.
Gottschalk, A., Glauche, I., Cicconi, S., Clark, R. E., & Roeder, I. (2020). Molecular dynamics during reduction of TKI dose reliably identify molecular recurrence after treatment cessation in CML.. Blood. doi:10.1182/blood.2019003395
Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1<sup>+</sup> Leukemia.
Schmidt, T., Kharabi Masouleh, B., Loges, S., Cauwenberghs, S., Fraisl, P., Maes, C., . . . Carmeliet, P. (2020). Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1<sup>+</sup> Leukemia.. Cancer cell, 37(1), 135-136. doi:10.1016/j.ccell.2019.12.010
2019
Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice
Clark, R. E. (2019). Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 14(6), 507-514. doi:10.1007/s11899-019-00548-2
FLAG-IDA and Ponatinib in Patients with Blast Phase Chronic Myeloid Leukaemia: Results from the Phase I/II UK Trials Acceleration Programme Matchpoint Trial
Copland, M., Slade, D., Byrne, J., Brock, K., De Lavallade, H., Craddock, C., . . . Yap, C. (2019). FLAG-IDA and Ponatinib in Patients with Blast Phase Chronic Myeloid Leukaemia: Results from the Phase I/II UK Trials Acceleration Programme Matchpoint Trial. In BLOOD Vol. 134. doi:10.1182/blood-2019-125591
Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)
Claudiani, S., Metelli, S., Kamvar, R., Szydlo, R., Khan, A., Byrne, J., . . . Apperley, J. F. (2019). Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML). BLOOD, 134. doi:10.1182/blood-2019-131500
Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis
Hughes, T. P., Saglio, G., Larson, R. A., Kantarjian, H. M., Kim, D. -W., Issaragrisil, S., . . . Hochhaus, A. (2019). Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis. In BLOOD Vol. 134. doi:10.1182/blood-2019-128761
Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin
Lauseker, M., Bachl, K., Turkina, A., Faber, E., Prejzner, W., Olsson-Stromberg, U., . . . Pfirrmann, M. (2019). Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin. AMERICAN JOURNAL OF HEMATOLOGY, 94(11), 1236-1243. doi:10.1002/ajh.25628
Cardiac, vascular, and hypertension safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial.
Cortes, J. E., Brummendorf, T. H., Gambacorti-Passerini, C., Clark, R. E., Leip, E., Viqueira, A., . . . Deininger, M. W. N. (2019). Cardiac, vascular, and hypertension safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37. Retrieved from https://www.webofscience.com/
Cancerous inhibitor of protein phosphatase 2A (CIP2A) modifies energy metabolism via 5′ AMP-activated protein kinase signalling in malignant cells
Austin, J. A., Jenkins, R. E., Austin, G. M., Glenn, M. A., Dunn, K., Scott, L., . . . Clark, R. E. (2019). Cancerous inhibitor of protein phosphatase 2A (CIP2A) modifies energy metabolism via 5′ AMP-activated protein kinase signalling in malignant cells. BIOCHEMICAL JOURNAL, 476, 2255-2269. doi:10.1042/BCJ20190121
De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial
Clark, R. E., Polydoros, F., Apperley, J. F., Milojkovic, D., Rothwell, K., Pocock, C., . . . Copland, M. (2019). De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. The Lancet Haematology, 6(7), E375-E383. doi:10.1016/S2352-3026(19)30094-8
Nilotinib-induced metabolic dysfunction: insights from a translational study using in vitro adipocyte models and patient cohorts
Sadiq, S., Owen, E., Foster, T., Knight, K., Wang, L., Pirmohamed, M., . . . Pushpakom, S. (2019). Nilotinib-induced metabolic dysfunction: insights from a translational study using in vitro adipocyte models and patient cohorts. Leukemia, 33, 1810-1814. doi:10.1038/s41375-018-0337-0
PF413 CARDIAC, VASCULAR, AND HYPERTENSION SAFETY OF BOSUTINIB VS IMATINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN THE BFORE TRIAL
Brümmendorf, T. H., Gambacorti‐Passerini, C., Clark, R., Leip, E., Viqueira, A., Kota, V., . . . Cortes, J. E. (2019). PF413 CARDIAC, VASCULAR, AND HYPERTENSION SAFETY OF BOSUTINIB VS IMATINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN THE BFORE TRIAL. HemaSphere, 3(S1), 159. doi:10.1097/01.hs9.0000559864.90626.f7
PS1167 INDIVIDUAL RESPONSE OF CML PATIENTS TO TKI DOSE REDUCTION CAN RELIABLY IDENTIFY PATIENTS WITH HIGH RISK OF MOLECULAR RELAPSE AFTER TREATMENT CESSATION
Gottschalk, A., Glauche, I., Clark, R., & Röder, I. (2019). PS1167 INDIVIDUAL RESPONSE OF CML PATIENTS TO TKI DOSE REDUCTION CAN RELIABLY IDENTIFY PATIENTS WITH HIGH RISK OF MOLECULAR RELAPSE AFTER TREATMENT CESSATION. HemaSphere, 3(S1), 530. doi:10.1097/01.hs9.0000562952.20361.f0
PS1182 REAL WORLD TYROSINE KINASE INHIBITOR TREATMENT PATHWAYS, MONITORING PATTERNS AND RESPONSES COMPARED WITH ELN RECOMMENDATIONS IN CHRONIC MYELOID LEUKAEMIA: FINAL ANALYSIS OF THE UK TARGET CML STUDY
Milojkovic, D., Cross, N. C., Ali, S., Byrne, J. L., Campbell, G., Dignan, F. L., . . . Mead, A. (2019). PS1182 REAL WORLD TYROSINE KINASE INHIBITOR TREATMENT PATHWAYS, MONITORING PATTERNS AND RESPONSES COMPARED WITH ELN RECOMMENDATIONS IN CHRONIC MYELOID LEUKAEMIA: FINAL ANALYSIS OF THE UK TARGET CML STUDY. HemaSphere, 3(S1), 538-539. doi:10.1097/01.hs9.0000563012.60265.ad
Cardiac, vascular, and hypertension safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial.
Cortes, J. E., Brümmendorf, T. H., Gambacorti-Passerini, C., Clark, R. E., Leip, E., Viqueira, A., . . . Deininger, M. W. N. (2019). Cardiac, vascular, and hypertension safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial.. Journal of Clinical Oncology, 37(15_suppl), 7051. doi:10.1200/jco.2019.37.15_suppl.7051
The effect on lymphocyte subsets of decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: data from the DESTINY trial
Austin, G. M., Knight, K., Bell, J., Carter, A., Heartin, E., Watson, D., . . . Clark, R. E. (2019). The effect on lymphocyte subsets of decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: data from the DESTINY trial. BRITISH JOURNAL OF HAEMATOLOGY, 185(4), 791-793. doi:10.1111/bjh.15629
Long-term survival of CML patients who received autologous HCT before and after the tyrosine kinase inhibitors ERA. Study on behalf of the EBMT CMWP
Michallet, M., Sobh, M., Hazelaar, S., Apperley, J., Milpied, N., Labussiere-Wallet, H., . . . Yakoub-Agha, I. (2019). Long-term survival of CML patients who received autologous HCT before and after the tyrosine kinase inhibitors ERA. Study on behalf of the EBMT CMWP. In BONE MARROW TRANSPLANTATION Vol. 54 (pp. 201-202). Retrieved from https://www.webofscience.com/
2018
DNA-Based Digital PCR for the Quantification of Residual Disease in CML - Sensitivity or Specificity?
Alikian, M., Ellwood, R., Tatarinova, O., Rose, G. D., Nteliopoulos, G., Gerrard, G., . . . Apperley, J. (2018). DNA-Based Digital PCR for the Quantification of Residual Disease in CML - Sensitivity or Specificity?. In BLOOD Vol. 132. doi:10.1182/blood-2018-99-117616
Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML
O'Brien, S., Cork, L., Bandeira, V., Bescoby, R., Foroni, L., Alaily, L., . . . Clark, R. (2018). Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML. In BLOOD Vol. 132. doi:10.1182/blood-2018-99-110128
Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial
Burnett, A. K., Das Gupta, E., Knapper, S., Khwaja, A., Sweeney, M., Kjeldsen, L., . . . Russel, N. H. (2018). Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial. HAEMATOLOGICA, 103(10), 1654-1661. doi:10.3324/haematol.2018.189514
Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial.
Russell, N., Burnett, A., Hills, R., Betteridge, S., Dennis, M., Jovanovic, J., . . . NCRI AML Working Group. (2018). Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial.. Blood, 132(13), 1452-1454. doi:10.1182/blood-2018-05-851824
CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML
Lucas, C. M., Scott, L. J., Carmell, N., Holcroft, A. K., Hills, R. K., Burnett, A. K., & Clark, R. E. (2018). CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML. Blood Advances, 2(9), 964-968. doi:10.1182/bloodadvances.2017013615
Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition
Mitchell, R., Hopcroft, L. E. M., Baquero, P., Allan, E. K., Hewit, K., James, D., . . . Helgason, G. V. (2018). Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 110(5), 467-478. doi:10.1093/jnci/djx236
De-escalation and discontinuation of tyrosine kinase inhibitor treatment in chronic myeloid leukaemia (CML) in stable major molecular response: 2-year data from the British DESTINY study
Clark, R. E., Polydoros, F., Apperley, J. F., Milojkovic, D., Pocock, C., Smith, G., . . . Copland, M. (2018). De-escalation and discontinuation of tyrosine kinase inhibitor treatment in chronic myeloid leukaemia (CML) in stable major molecular response: 2-year data from the British DESTINY study. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 181 (pp. 6). Retrieved from https://www.webofscience.com/
Efficacy and Safety of First-Line Bosutinib versus Imatinib in the BFORE trial: 18-Month Follow-up
Clark, R. E., Gambacorti-Passerini, C., Deininger, M., Mauro, M. J., Chuah, C., Kim, D. -W., . . . Cortes, J. E. (2018). Efficacy and Safety of First-Line Bosutinib versus Imatinib in the BFORE trial: 18-Month Follow-up. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 181 (pp. 7-8). Retrieved from https://www.webofscience.com/
First report from the UK National Registry for chronic myeloid leukaemia: Analysis of baseline characteristics of 435 patients
Nesr, G. N. G., Szydlo, R., Braithwaite, B., Frackleton, S., Apperley, J., Milojkovic, D., . . . Clark, R. E. (2018). First report from the UK National Registry for chronic myeloid leukaemia: Analysis of baseline characteristics of 435 patients. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 181 (pp. 48). Retrieved from https://www.webofscience.com/
In chronic myeloid leukaemia cells, the oncoprotein CIP2A binds directly to and alters expression of many cellular proteins, independent of effects on protein phosphatase 2A (PP2A)
Austin, J. A., Lucas, C. M., Jenkins, R. E., Dunn, K., Scott, L. J., Glenn, M. A., . . . Clark, R. E. (2018). In chronic myeloid leukaemia cells, the oncoprotein CIP2A binds directly to and alters expression of many cellular proteins, independent of effects on protein phosphatase 2A (PP2A). In BRITISH JOURNAL OF HAEMATOLOGY Vol. 181 (pp. 52-53). Retrieved from https://www.webofscience.com/
Snížení terapeutické dávky TKI před kompletním vysazením léčby zlepšuje šanci na úspěšné zastavení léčby u pacientů s chronickou myeloidní leukemií (CML): dvouleté výsledky britské studie DESTINY
Clark, R., Polydoros, F., Apperley, J., & Koblihová, P. J. (2018). Snížení terapeutické dávky TKI před kompletním vysazením léčby zlepšuje šanci na úspěšné zastavení léčby u pacientů s chronickou myeloidní leukemií (CML): dvouleté výsledky britské studie DESTINY. Transfuze a Hematologie Dnes, 24(1), 60.
2017
E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy
Claudiani, S., Apperley, J. F., Gale, R. P., Clark, R., Szydlo, R., Deplano, S., . . . Milojkovic, D. (2017). E14a2 <i>BCR-ABL1</i> transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy.. Haematologica, 102(8), e297-e299. doi:10.3324/haematol.2017.168740
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial
Clark, R. E., Polydoros, F., Apperley, J. F., Milojkovic, D., Pocock, C., Smith, G., . . . Copland, M. (2017). De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. The Lancet Haematology, 4(7), E310-E316. doi:10.1016/S2352-3026(17)30066-2
NILOTINIB-INDUCED METABOLIC DYSFUNCTION: INSIGHTS FROM A TRANSLATIONAL PILOT STUDY USING <i>IN VITRO</i> ADIPOCYTE MODELS AND PATIENT COHORTS
Sadiq, S., Owen, E., Foster, T., Knight, K., Wang, L., Pirmohamed, M., . . . Pushpakom, S. (2017). NILOTINIB-INDUCED METABOLIC DYSFUNCTION: INSIGHTS FROM A TRANSLATIONAL PILOT STUDY USING <i>IN VITRO</i> ADIPOCYTE MODELS AND PATIENT COHORTS. Poster session presented at the meeting of Unknown Conference. Retrieved from https://www.webofscience.com/
Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia
Ben-Batalla, I., Erdmann, R., Jorgensen, H., Mitchell, R., Ernst, T., Von Amsberg, G., . . . Loges, S. (2017). Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia. CLINICAL CANCER RESEARCH, 23(9), 2289-2300. doi:10.1158/1078-0432.CCR-16-1930
Cardiologist's perspective to the European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia Reply
Steegmann, J. L., Baccarani, M., & Clark, R. E. (2017). Cardiologist's perspective to the European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia Reply. LEUKEMIA, 31(3), 772-773. doi:10.1038/leu.2016.337
Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.
Hoffmann, V. S., Baccarani, M., Hasford, J., Castagnetti, F., Di Raimondo, F., Casado, L. F., . . . Hehlmann, R. (2017). Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.. Leukemia, 31(3), 593-601. doi:10.1038/leu.2016.246
A comparison of clofarabine with Ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.
Burnett, A. K., Russell, N. H., Hills, R. K., Kell, J., Nielsen, O. J., Dennis, M., . . . Clark, R. E. (2017). A comparison of clofarabine with Ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.. Leukemia, 31, 310-317. doi:10.1038/leu.2016.225
2016
Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia
Kinstrie, R., Karamitros, D., Goardon, N., Morrison, H., Hamblin, M., Robinson, L., . . . Vyas, P. (2016). Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia. BLOOD ADVANCES, 1(3), 160-169. doi:10.1182/bloodadvances.2016000810
Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study
Clark, R. E., Polydoros, F., Apperley, J. F., Pocock, C., Smith, G., Byrne, J. L., . . . Copland, M. (2016). Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study. In BLOOD Vol. 128. doi:10.1182/blood.V128.22.938.938
An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation
Ferguson, P., Hills, R. K., Grech, A., Betteridge, S., Kjeldsen, L., Dennis, M., . . . Craddock, C. (2016). An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation. HAEMATOLOGICA, 101(11), 1351-1358. doi:10.3324/haematol.2016.148825
Evaluating the use of plerixafor in stem cell mobilisation - an economic analysis of the PHANTASTIC trial
Martin, A. P., Richards, S., Haycox, A., Houten, R., McLeod, C., Braithwaite, B., . . . Clark, R. E. (2016). Evaluating the use of plerixafor in stem cell mobilisation - an economic analysis of the PHANTASTIC trial. JOURNAL OF CLINICAL APHERESIS, 31(5), 434-442. doi:10.1002/jca.21433
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
Steegmann, J. L., Baccarani, M., Breccia, M., Casado, L. F., Garcia-Gutierrez, V., Hochhaus, A., . . . Clark, R. E. (2016). European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. LEUKEMIA, 30(8), 1648-1671. doi:10.1038/leu.2016.104
CLONAL STRUCTURES OF LEUKAEMIA STEM CELL POPULATIONS IN MYELOID BLAST PHASE CHRONIC MYELOID LEUKAEMIA
Karamitros, D., Morrison, H., Kinstrie, R., Goardon, N., Clark, R. E., Copland, M., & Vyas, P. (2016). CLONAL STRUCTURES OF LEUKAEMIA STEM CELL POPULATIONS IN MYELOID BLAST PHASE CHRONIC MYELOID LEUKAEMIA. In HAEMATOLOGICA Vol. 101 (pp. 234-235). Retrieved from https://www.webofscience.com/
THE ADVERSE EFFECTS OF CANCEROUS INHIBITOR OF PROTEIN PHOSPHATASE 2A, ARE LINKED WITH REDUCTION OF FUNCTIONAL B56GAMMA, A REGULATORY SUBUNIT OF PROTEIN PHOSPHATASE 2A, IN CHRONIC MYELOID LEUKAEMIA
Austin, J. A., Lucas, C. M., Scott, L., Holcroft, A., Wang, L., & Clark, R. E. (2016). THE ADVERSE EFFECTS OF CANCEROUS INHIBITOR OF PROTEIN PHOSPHATASE 2A, ARE LINKED WITH REDUCTION OF FUNCTIONAL B56GAMMA, A REGULATORY SUBUNIT OF PROTEIN PHOSPHATASE 2A, IN CHRONIC MYELOID LEUKAEMIA. In HAEMATOLOGICA Vol. 101 (pp. 182). Retrieved from https://www.webofscience.com/
High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-X-L in chronic myeloid leukemia
Lucas, C. M., Milani, M., Butterworth, M., Carmell, N., Scott, L. J., Clark, R. E., . . . Varadarajan, S. (2016). High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-X-L in chronic myeloid leukemia. LEUKEMIA, 30(6), 1273-1281. doi:10.1038/leu.2016.42
Defining The Dose Of Gemtuzumab Ozogamicin In Combination With Induction Chemotherapy In Acute Myeloid Leukemia: A Comparison Of 3 Mg/M2 With 6 Mg/M2 In The NCRI AML17 Trial
Burnett, A., Cavenagh, J., Russell, N., Hills, R., Kell, J., Jones, G., . . . Grp, U. K. N. C. R. I. A. M. L. S. (2016). Defining The Dose Of Gemtuzumab Ozogamicin In Combination With Induction Chemotherapy In Acute Myeloid Leukemia: A Comparison Of 3 Mg/M2 With 6 Mg/M2 In The NCRI AML17 Trial. Haematologica: the hematology journal, 101(6), 724-731. doi:10.3324/haematol.2016.141937
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
Hochhaus, A., Saglio, G., Hughes, T. P., Larson, R. A., Kim, D. -W., Issaragrisil, S., . . . Kantarjian, H. M. (2016). Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. LEUKEMIA, 30(5), 1044-1054. doi:10.1038/leu.2016.5
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
Lipton, J. H., Chuah, C., Guerci-Bresler, A., Rosti, G., Simpson, D., Assouline, S., . . . Investigators, E. P. I. C. (2016). Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. The Lancet Oncology, 17(5), 612-621. doi:10.1016/S1470-2045(16)00080-2
De-escalation of tyrosine kinase inhibitor treatment in chronic myeloid leukaemia patients with excellent molecular responses: Initial safety results from the DESTINY trial
Clark, R. E., Polydoros, F., Apperley, J. F., Pocock, C., Smith, G., Salim, R., . . . Copland, M. (2016). De-escalation of tyrosine kinase inhibitor treatment in chronic myeloid leukaemia patients with excellent molecular responses: Initial safety results from the DESTINY trial. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 173 (pp. 12). Retrieved from https://www.webofscience.com/
T cell subsets do not alter on decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: Data from the DESTINY trial
Austin, G., Knight, K., Bell, J., Foroni, L., Salim, R., Christmas, S. E., . . . Clark, R. E. (2016). T cell subsets do not alter on decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: Data from the DESTINY trial. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 173 (pp. 119). Retrieved from https://www.webofscience.com/
The Cdk2 inhibitor, Purvalanol A, induces apoptosis is myeloid cells via p38-MAPK dependent turnover of Mcl-1
Phoomvuthisarn, P., Wright, H. L., Clark, R. E., Mutirangura, A., & Edwards, S. W. (2016). The Cdk2 inhibitor, Purvalanol A, induces apoptosis is myeloid cells via p38-MAPK dependent turnover of Mcl-1. In EUROPEAN JOURNAL OF CLINICAL INVESTIGATION Vol. 46 (pp. 81). Retrieved from https://www.webofscience.com/
2015
An Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy
Ferguson, P., Hills, R. K., Grech, A., Betteridge, S., Kjeldsen, L., Dennis, M., . . . Craddock, C. (2015). An Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy. In BLOOD Vol. 126. doi:10.1182/blood.V126.23.559.559
Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia
Labeit, A. M., Copland, M., Cork, L. M., Hedgley, C. A., Foroni, L., Osborne, W. L., . . . O'Brien, S. G. (2015). Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia. In BLOOD Vol. 126. Retrieved from https://www.webofscience.com/
BGB324 Inhibits BCR-ABL TKI-Resistant Chronic Myeloid Leukemia
Ben Batalla, I., Erdmann, R., Jorgensen, H., Mitchell, R., Ernst, T., von Amsberg, G., . . . Loges, S. (2015). BGB324 Inhibits BCR-ABL TKI-Resistant Chronic Myeloid Leukemia. In BLOOD Vol. 126. Retrieved from https://www.webofscience.com/
PP2A Inhibition By CIP2A or SETBP1 Leads to Elevated Levels of AKT S473 Which Can be Used As a Biomarker of Outcome in Acute Myeloid Leukaemia
Hills, R. K., Lucas, C. M., Scott, L. J., Carmell, N., Holcroft, A. K., & Clark, R. E. (2015). PP2A Inhibition By CIP2A or SETBP1 Leads to Elevated Levels of AKT S473 Which Can be Used As a Biomarker of Outcome in Acute Myeloid Leukaemia. In BLOOD Vol. 126. Retrieved from https://www.webofscience.com/
Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry
Hoffmann, V. S., Baccarani, M., Hasford, J., Lindoerfer, D., Burgstaller, S., Sertic, D., . . . Hehlmann, R. (2015). Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry. In BLOOD Vol. 126. Retrieved from https://www.webofscience.com/
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial
Burnett, A. K., Russell, N. H., Hills, R. K., Bowen, D., Kell, J., Knapper, S., . . . Grimwade, D. (2015). Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. The Lancet Oncology, 16(13), 1295-1305. doi:10.1016/S1470-2045(15)00193-X
A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemia
Russell, N. H., Kjeldsen, L., Craddock, C., Pagliuca, A., Yin, J. A., Clark, R. E., . . . Burnett, A. K. (2015). A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemia. LEUKEMIA, 29(7), 1478-1484. doi:10.1038/leu.2014.319
Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients
Lucas, C., Harris, B., Holcroft, A., Scott, L., Carmell, N., McDonald, E., . . . Clark, R. (2015). Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients. Leukemia, 29(7), 1514-1523. doi:10.1038/leu.2015.71
Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial
Mead, A. J., Milojkovic, D., Knapper, S., Garg, M., Chacko, J., Farquharson, M., . . . Harrison, C. (2015). Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial. BRITISH JOURNAL OF HAEMATOLOGY, 170(1), 29-39. doi:10.1111/bjh.13379
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients
Burnett, A. K., Russell, N. H., Hills, R. K., Kell, J., Cavenagh, J., Kjeldsen, L., . . . Clark, R. (2015). A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood, 125(25), 3878-3885. doi:10.1182/blood-2015-01-623447
A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia
Burnett, A. K., Russell, N., Hills, R. K., Panoskaltsis, N., Khwaja, A., Hemmaway, C., . . . Milligan, D. (2015). A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia. Leukemia, 29(6), 1312-1319. doi:10.1038/leu.2015.38
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries
Hoffmann, V. S., Baccarani, M., Hasford, J., Lindoerfer, D., Burgstaller, S., Sertic, D., . . . Hehlmann, R. (2015). The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. LEUKEMIA, 29(6), 1336-1343. doi:10.1038/leu.2015.73
Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia
Dennis, M., Russell, N., Hills, R. K., Hemmaway, C., Panoskaltsis, N., McMullin, M. -F., . . . Burnett, A. K. (2015). Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. BLOOD, 125(19), 2923-2932. doi:10.1182/blood-2014-10-608117
C-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia
Lucas, C., Harris, B., Giannoudis, A., & Clark, R. (2015). C-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia. Haematologica, 100(05), e179-e182. doi:10.3324/haematol.2014.115691
Onset and outcome of pregnancy after autologous haematopoietic SCT (AHSCT) for autoimmune diseases: a retrospective study of the EBMT autoimmune diseases working party (ADWP)
Snarski, E., Snowden, J. A., Oliveira, M. C., Simoes, B., Badoglio, M., Carlson, K., . . . Farge, D. (2015). Onset and outcome of pregnancy after autologous haematopoietic SCT (AHSCT) for autoimmune diseases: a retrospective study of the EBMT autoimmune diseases working party (ADWP). BONE MARROW TRANSPLANTATION, 50(2), 216-220. doi:10.1038/bmt.2014.248
<i>PTCH1</i> expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase
Alonso-Dominguez, J. M., Grinfeld, J., Alikian, M., Marin, D., Reid, A., Daghistani, M., . . . Gerrard, G. (2015). <i>PTCH1</i> expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase. AMERICAN JOURNAL OF HEMATOLOGY, 90(1), 20-26. doi:10.1002/ajh.23857
APL of all risk groups is highly curable with a chemo-free combination of attenuated arsenic trioxide and ATRA
Burnett, A. K., Russell, N. H., Hills, R. K., Khwaja, A., Cavenagh, J., Friis, L., . . . Grimwade, D. (2015). APL of all risk groups is highly curable with a chemo-free combination of attenuated arsenic trioxide and ATRA. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 169 (pp. 16). Retrieved from https://www.webofscience.com/
EFFICACY AND SAFETY OF NILOTINIB VS IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: 6-YEAR FOLLOW-UP OF ENESTND
Hughes, T. P., Larson, R. A., Kim, D. W., Issaragrisil, S., le Coutre, P. D., Lobo, C., . . . Kantarjian, H. M. (2015). EFFICACY AND SAFETY OF NILOTINIB VS IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: 6-YEAR FOLLOW-UP OF ENESTND. In HAEMATOLOGICA Vol. 100 (pp. 61). Retrieved from https://www.webofscience.com/
Evidence that the pregnane X and retinoid receptors PXR, RAR and RXR may regulate transcription of the transporter <i>hOCT1</i> in chronic myeloid leukaemia cells
Austin, G., Holcroft, A., Rinne, N., Wang, L., & Clark, R. E. (2015). Evidence that the pregnane X and retinoid receptors PXR, RAR and RXR may regulate transcription of the transporter <i>hOCT1</i> in chronic myeloid leukaemia cells. EUROPEAN JOURNAL OF HAEMATOLOGY, 94(1), 74-78. doi:10.1111/ejh.12409
Systematic review to examine the clinical effectiveness and tolerability of systemic anti-cancer therapy for older people with chronic myeloid leukaemia
Bates, V., Pilkington, G. M., Dickson, R. C., Boland, A., Dundar, Y., & Clark, R. (n.d.). Systematic review to examine the clinical effectiveness and tolerability of systemic anti-cancer therapy for older people with chronic myeloid leukaemia.
2014
A Comparison of Single Dose Gemtuzumab Ozogamicin 3mg/m<SUP>2</SUP> and 6mg/m<SUP>2</SUP> Combined with Induction Chemotherapy in Younger Patients with AML: Data from the UK NCRI AML17 Trial
Burnett, A. K., Russell, N., Hills, R. K., Cavenagh, J., Kell, J., Jones, G., . . . Clark, R. E. (2014). A Comparison of Single Dose Gemtuzumab Ozogamicin 3mg/m<SUP>2</SUP> and 6mg/m<SUP>2</SUP> Combined with Induction Chemotherapy in Younger Patients with AML: Data from the UK NCRI AML17 Trial. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/
A Randomised Assessment of Vosaroxin Monotherapy and Vosaroxin Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia
Dennis, M., Russell, N. H., Panoskaltsis, N., Hemmaway, C. J., Milligan, D., Clark, R. E., . . . Burnett, A. K. (2014). A Randomised Assessment of Vosaroxin Monotherapy and Vosaroxin Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/
A Randomised Comparison of Daunorubicin 90mg/m<SUP>2</SUP> Vs 60mg/m<SUP>2</SUP> in AML Induction: Results from the UK NCRI AML17 Trial in 1206 Patients
Burnett, A. K., Russell, N., Hills, R. K., Kell, J., Cavenagh, J., Kjeldsen, L., . . . Clark, R. E. (2014). A Randomised Comparison of Daunorubicin 90mg/m<SUP>2</SUP> Vs 60mg/m<SUP>2</SUP> in AML Induction: Results from the UK NCRI AML17 Trial in 1206 Patients. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/
A Randomised Comparison of the Sequential Addition of the FLT3 Inhibitor Lestaurtinib (CEP701) to Standard First Line Chemotherapy for FLT3-Mutated Acute Myeloid Leukemia: The UK Experience
Knapper, S., Hills, R. K., Cavenagh, J. D., Kjeldsen, L., Hunter, A. E., Clark, R. E., . . . Burnett, A. K. (2014). A Randomised Comparison of the Sequential Addition of the FLT3 Inhibitor Lestaurtinib (CEP701) to Standard First Line Chemotherapy for FLT3-Mutated Acute Myeloid Leukemia: The UK Experience. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/
BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant
Erdmann, R., Jorgensen, H., Ben-Batalla, I., Kruse, N., Micklem, D., von Amsberg, G., . . . Loges, S. (2014). BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/
Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials
Baccarani, M., Hoffmann, V. S., Rosti, G., Castagnetti, F., Saussele, S., Guilhot, J., . . . Lindoerfer, D. (2014). Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials. BLOOD, 124(21). Retrieved from https://www.webofscience.com/
CMV~IMPACT: Results of a Randomized Controlled Trial of Immuno-Prophylactic Adoptive Cellular Therapy following Sibling Donor Allogeneic HSCT
Peggs, K. S., Tholouli, E., Chakraverty, R., Nikolousis, E., Bloor, A., Devereux, S., . . . Moss, P. (2014). CMV~IMPACT: Results of a Randomized Controlled Trial of Immuno-Prophylactic Adoptive Cellular Therapy following Sibling Donor Allogeneic HSCT. Blood, 124(21), 1109. doi:10.1182/blood.v124.21.1109.1109
Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd
Larson, R. A., Kim, D. -W., Issaragrilsil, S., le Coutre, P., Dorlhiac Llacer, P. E., Etienne, G., . . . Hughes, T. P. (2014). Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd. In BLOOD Vol. 124. doi:10.1182/blood.V124.21.1804.1804
Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd
Larson, R. A., Kim, D. -W., Issaragrilsil, S., le Coutre, P., Dorlhiac Llacer, P. E., Etienne, G., . . . Hughes, T. P. (2014). Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd. Blood, 124(21), 4541. doi:10.1182/blood.v124.21.4541.4541
Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML)
Lipton, J. H., Chuah, C., Guerci-Bresler, A., Rosti, G., Simpson, D., Assouline, S., . . . Deininger, M. W. (2014). Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML). In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/
Incidence of CML in Europe -- a Comparison of 19 European Countries with US SEER Data
Hoffmann, V. S., Lindoerfer, D., Thaler, J., Boris, L., Melanthiou, F., Mayer, J., . . . Baccarani, M. (2014). Incidence of CML in Europe -- a Comparison of 19 European Countries with US SEER Data. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/
Leukemia Stem Cell Potential of Different Progenitor Subpopulations in Myeloid Blast Phase CML
Kinstrie, R., Karamitros, D., Goardon, N., Morrison, H., Clark, R. E., Vyas, P., & Copland, M. (2014). Leukemia Stem Cell Potential of Different Progenitor Subpopulations in Myeloid Blast Phase CML. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/
Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML
O'Brien, S. G., Hedgley, C., Adams, S., Foroni, L., Apperley, J. F., Holyoake, T. L., . . . Clark, R. E. (2014). Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/
Dual Glutathione-<i>S</i>-Transferase-θ1 and -μ1 Gene Deletions Determine Imatinib Failure in Chronic Myeloid Leukemia
Davies, A., Giannoudis, A., Zhang, J. E., Austin, G., Wang, L., Holyoake, T. L., . . . Clark, R. E. (2014). Dual Glutathione-<i>S</i>-Transferase-θ1 and -μ1 Gene Deletions Determine Imatinib Failure in Chronic Myeloid Leukemia. CLINICAL PHARMACOLOGY & THERAPEUTICS, 96(6), 694-703. doi:10.1038/clpt.2014.176
Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia
Lucas, C. M., Harris, R. J., Giannoudis, A., McDonald, E., & Clark, R. E. (2014). Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia. HAEMATOLOGICA, 99(11), 1710-1715. doi:10.3324/haematol.2013.101972
Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients
Clark, R. E., Bell, J., Clark, J. O., Braithwaite, B., Vithanarachchi, U., McGinnity, N., . . . Salim, R. (2014). Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients. BLOOD CANCER JOURNAL, 4. doi:10.1038/bcj.2014.79
ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM).
Larson, R. A., Kim, D. -W., Jootar, S., Pasquini, R., Clark, R. E., Lobo, C., . . . Hughes, T. P. (2014). ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 7073). doi:10.1200/jco.2014.32.15_suppl.7073
Tuesday 29th April 2014 Free Communication John Goldman Memorial Symposium
O'Brien, S. G., Clark, R. E., Hedgley, C., Apperley, J., Foroni, L., Pocock, C., . . . Goldman, J. M. (2014). Tuesday 29th April 2014 Free Communication John Goldman Memorial Symposium. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 165 (pp. 1). doi:10.1111/bjh.12803
A NATIONAL EXPERIENCE OF THE USE OF PONATINIB IN PATIENTS MULTIPLE TYROSINE KINASE INHIBITORS CONFIRMS EFFICACY IN A HEAVILY PRE-TREATED COHORT OF PATIENTS WITH PH plus LEUKAEMIAS
Milojkovic, D., Bakir, A., Whitehead, L., Byrne, J., Clark, R. E., Copland, M., . . . Apperley, J. (2014). A NATIONAL EXPERIENCE OF THE USE OF PONATINIB IN PATIENTS MULTIPLE TYROSINE KINASE INHIBITORS CONFIRMS EFFICACY IN A HEAVILY PRE-TREATED COHORT OF PATIENTS WITH PH plus LEUKAEMIAS. In HAEMATOLOGICA Vol. 99 (pp. 335). Retrieved from https://www.webofscience.com/
Alox5 is down-regulated at diagnosis of chronic myeloid leukaemia
Lucas, C. M., Harris, R. J., Giannoudis, A., McDonald, E., & Clark, R. E. (2014). Alox5 is down-regulated at diagnosis of chronic myeloid leukaemia. Haematologica, epub, September 5th 2014.
CMV∼IMPACT: Results of a Randomized Controlled Trial of Immuno-Prophylactic Adoptive Cellular Therapy following Sibling Donor Allogeneic HSCT
Peggs, K. S., Tholouli, E., Chakraverty, R., Nikolousis, E., Bloor, A., Devereux, S., . . . Moss, P. (2014). CMV∼IMPACT: Results of a Randomized Controlled Trial of Immuno-Prophylactic Adoptive Cellular Therapy following Sibling Donor Allogeneic HSCT. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/
Fertility recovery and pregnancy after autologous hematopoietic stem cell transplantation for autoimmune diseases: a retrospective study of the EBMT Autoimmune Diseases Working Party
Snarski, E., Snowden, J. A., Oliveira, M. C., Simoes, B., Badoglio, M., Carlson, K., . . . Farge, D. (2014). Fertility recovery and pregnancy after autologous hematopoietic stem cell transplantation for autoimmune diseases: a retrospective study of the EBMT Autoimmune Diseases Working Party. Blood & Marrow Transplantation, in pre, accepted 18 Sept 2014.
Ikaros transcripts Ik6/10 and levels of full-length transcript are critical for chronic myeloid leukaemia blast crisis transformation
Wang, L. H., Howarth, A., & Clark, R. E. (2014). Ikaros transcripts Ik6/10 and levels of full-length transcript are critical for chronic myeloid leukaemia blast crisis transformation. Leukemia, 28, 1745-1747. doi:10.1038/leu.2014.99
PLERIXAFOR IS COST-EFFECTIVE FOR FIRST LINE STEM CELL MOBILISATION: INDIVIDUAL PATIENT COSTING ANALYSIS OF THE LIVERPOOL PHANTASTIC TRIAL
Haycox, A., Richards, S., & Clark, R. E. (2014). PLERIXAFOR IS COST-EFFECTIVE FOR FIRST LINE STEM CELL MOBILISATION: INDIVIDUAL PATIENT COSTING ANALYSIS OF THE LIVERPOOL PHANTASTIC TRIAL. In HAEMATOLOGICA Vol. 99 (pp. 490-491). Retrieved from https://www.webofscience.com/
THE EUTOS POPULATION BASED REGISTRY - INCIDENCES OF CML ACROSS EUROPE
Hoffmann, V., Lindoerfer, D., Thaler, J., Labar, B., Melanthiou, F., Mayer, J., . . . Baccarani, M. (2014). THE EUTOS POPULATION BASED REGISTRY - INCIDENCES OF CML ACROSS EUROPE. In HAEMATOLOGICA Vol. 99 (pp. 72). Retrieved from https://www.webofscience.com/
THE EUTOS POPULATION-BASED REGISTRY: EVALUATION OF BASELINE CHARACTERISTICS AND FIRST TREATMENT CHOICES OF 2983 NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) PATIENTS FROM 20 EUROPEAN COUNTRIES
Lindoerfer, D., Hoffmann, V. S., Rosti, G., Castagnetti, F., Saussele, S., Guilhot, J., . . . Baccarani, M. (2014). THE EUTOS POPULATION-BASED REGISTRY: EVALUATION OF BASELINE CHARACTERISTICS AND FIRST TREATMENT CHOICES OF 2983 NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) PATIENTS FROM 20 EUROPEAN COUNTRIES. In HAEMATOLOGICA Vol. 99 (pp. 238-239). Retrieved from https://www.webofscience.com/
TRANSCRIPT LEVELS OF THE HEDGEHOG PATHWAY MEMBERS PTCH1 AND SMO ARE PREDICTIVE OF IMATINIB FAILURE IN PRE-TREATMENT CHRONIC MYELOID LEUKAEMIA
Gerrard, G., Hagkarim, N. C., Szydlo, R., Alikian, M., Alonso-Dominguez, J. M., Grinfeld, J., . . . Foroni, L. (2014). TRANSCRIPT LEVELS OF THE HEDGEHOG PATHWAY MEMBERS PTCH1 AND SMO ARE PREDICTIVE OF IMATINIB FAILURE IN PRE-TREATMENT CHRONIC MYELOID LEUKAEMIA. In HAEMATOLOGICA Vol. 99 (pp. 510). Retrieved from https://www.webofscience.com/
The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia
Giannoudis, A., Davies, A., Harris, B., Lucas, C., Pirmohamed, M., & Clark, R. (2014). The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia. Leukemia, 28(6), 1360-1363. doi:10.1038/leu.2014.38
2013
A common novel splice variant of <i>SLC22A1</i> (<i>OCT1</i>) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia
Grinfeld, J., Gerrard, G., Alikian, M., Alonso-Dominguez, J., Ale, S., Valganon, M., . . . Foroni, L. (2013). A common novel splice variant of <i>SLC22A1</i> (<i>OCT1</i>) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 163(5), 631-639. doi:10.1111/bjh.12591
Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up.
Gallipoli, P., Stobo, J., Heaney, N., Nicolini, F. E., Clark, R., Wilson, G., . . . Holyoake, T. L. (2013). Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up.. British journal of haematology, 163(5), 674-676. doi:10.1111/bjh.12532
Dose Interruption/Reduction Of Tyrosine Kinase Inhibitors In The First 3 Months Of Treatment of CML Is Associated With Inferior Early Molecular Responses and Predicts For An Increased Likelihood Of Discontinuation Of The 1st Line Agent
Apperley, J. F., Szydlo, R. M., Gerrard, G., McCue, J. R., Wardle, J., Clark, R. E., . . . Foroni, L. (2013). Dose Interruption/Reduction Of Tyrosine Kinase Inhibitors In The First 3 Months Of Treatment of CML Is Associated With Inferior Early Molecular Responses and Predicts For An Increased Likelihood Of Discontinuation Of The 1st Line Agent. Blood, 122(21), 93. doi:10.1182/blood.v122.21.93.93
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., . . . Hehlmann, R. (2013). European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.. Blood, 122(6), 872-884. doi:10.1182/blood-2013-05-501569
A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia.
Francis, S., Lucas, C., Lane, S., Wang, L., Watmough, S., Knight, K., . . . Clark, R. E. (2013). A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia.. Leukemia research, 37(7), 752-758. doi:10.1016/j.leukres.2013.04.003
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.
Experts in Chronic Myeloid Leukemia. (2013). The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.. Blood, 121(22), 4439-4442. doi:10.1182/blood-2013-03-490003
Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies
Neelakantan, P., Gerrard, G., Lucas, C., Milojkovic, D., May, P., Wang, L., . . . Marin, D. (2013). Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. BLOOD, 121(14), 2739-2742. doi:10.1182/blood-2012-11-466037
The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia
Giannoudis, A., Wang, L., Jorgensen, A. L., Xinarianos, G., Davies, A., Pushpakom, S., . . . Clark, R. E. (2013). The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. BLOOD, 121(4), 628-637. doi:10.1182/blood-2012-01-405035
Can the combined assessment of BCR-ABL1 transcript levels at 3 and 6 months improve the prognostic value of the 3 month measurement for CML patients who start treatment with tyrosine kinase inhibitors? Implications for early intervention strategies
Neelakantan, P., Gerrard, G., Lucas, C. M., Hedgley, C., Milojkovic, D., May, P., . . . Marin, D. (2013). Can the combined assessment of BCR-ABL1 transcript levels at 3 and 6 months improve the prognostic value of the 3 month measurement for CML patients who start treatment with tyrosine kinase inhibitors? Implications for early intervention strategies. Blood, 121, 2739-2742.
Pulsed imatinib with or without G-CSF is a safe treatment approach and potentially improves molecular responses in CML patients in complete cytogenetic response compared to continuous imatinib: results from 5 years follow-up of a pilot study (GIMI)
Gallipoli, P., Stobo, J., Heaney, N., Kaeda, J., Nicolini, F. E., Clark, R. E., . . . Holyoake, T. L. (2013). Pulsed imatinib with or without G-CSF is a safe treatment approach and potentially improves molecular responses in CML patients in complete cytogenetic response compared to continuous imatinib: results from 5 years follow-up of a pilot study (GIMI). British Journal of Haematology, 163, 674-676.
Response to the letter to the Editor. Tzvetkov et al, "The hOCT1 SNPs Met420del and Met408Val alter imatinib uptake: Does the apparently predictive haplotype Met408-Del420 really exist"?
Giannoudis, A., Pirmohamed, M., & Clark, R. E. (2013). Response to the letter to the Editor. Tzvetkov et al, "The hOCT1 SNPs Met420del and Met408Val alter imatinib uptake: Does the apparently predictive haplotype Met408-Del420 really exist"?. Blood e-letters. Retrieved from http://bloodjournal.hematologylibrary.org/
The hOCT1 single nucleotide polymorphisms M420del and M408V alter imatinib uptake and modify clinical outcome in imatinib treated chronic myeloid leukaemia
Giannoudis, A., Wang, L., Jorgensen, A. L., Xinarianos, G., Davies, A., Pushpakom, S., . . . Clark, R. E. (2013). The hOCT1 single nucleotide polymorphisms M420del and M408V alter imatinib uptake and modify clinical outcome in imatinib treated chronic myeloid leukaemia. Blood, 121, 628-637.
2012
A Novel Splice Site Variant of hOCT-1 and Response to Imatinib.
Grinfeld, J., Alonso-Dominguez, J. M., Alikian, M., Valgañón, M., Nteliopoulos, G., White, D. L., . . . Gerrard, G. (2012). A Novel Splice Site Variant of hOCT-1 and Response to Imatinib.. Blood, 120(21), 2555. doi:10.1182/blood.v120.21.2555.2555
PTCH1 Expression At Diagnosis Reliably Predicts Treatment Failure in Imatinib-Treated Chronic Myeloid Leukaemia Patients
Alonso-Dominguez, J. M., Grinfeld, J., Alikian, M., Marin, D., Reid, A., Daghistani, M., . . . Gerrard, G. (2012). PTCH1 Expression At Diagnosis Reliably Predicts Treatment Failure in Imatinib-Treated Chronic Myeloid Leukaemia Patients. In BLOOD Vol. 120. doi:10.1182/blood.V120.21.875.875
Erratum: Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
Larson, R. A., Hochhaus, A., Hughes, T. P., Clark, R. E., Etienne, G., Kim, D. -W., . . . Kantarjian, H. M. (2012). Erratum: Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia, 26(10), 2302. doi:10.1038/leu.2012.175
Serine 162, an Essential Residue for the Mitochondrial Localization, Stability and Anti-Apoptotic Function of Mcl-1
Thomas, L. W., Lam, C., Clark, R. E., White, M. R. H., Spiller, D. G., Moots, R. J., & Edwards, S. W. (2012). Serine 162, an Essential Residue for the Mitochondrial Localization, Stability and Anti-Apoptotic Function of Mcl-1. PLOS ONE, 7(9). doi:10.1371/journal.pone.0045088
Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.
Ali, S., Sergeant, R., O'Brien, S. G., Foroni, L., Hedgley, C., Gerrard, G., . . . Rezvani, K. (2012). Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.. Blood, 120(3), 697-698. doi:10.1182/blood-2012-04-421016
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib
Marin, D., Hedgley, C., Clark, R. E., Apperley, J., Foroni, L., Milojkovic, D., . . . O'Brien, S. (2012). Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. BLOOD, 120(2), 291-294. doi:10.1182/blood-2012-01-407486
Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet.
Guilhot, J., Baccarani, M., Clark, R. E., Cervantes, F., Guilhot, F., Hochhaus, A., . . . Hehlmann, R. (2012). Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet.. Blood, 119(25), 5963-5971. doi:10.1182/blood-2011-10-383711
Haematopoietic stem cell transplantation (HSCT) in severe autoimmune diseases: analysis of UK outcomes from the British Society of Blood and Marrow Transplantation (BSBMT) data registry 1997-2009.
Snowden, J. A., Pearce, R. M., Lee, J., Kirkland, K., Gilleece, M., Veys, P., . . . BSBMT Clinical Trials Committee. (2012). Haematopoietic stem cell transplantation (HSCT) in severe autoimmune diseases: analysis of UK outcomes from the British Society of Blood and Marrow Transplantation (BSBMT) data registry 1997-2009.. British journal of haematology, 157(6), 742-746. doi:10.1111/j.1365-2141.2012.09122.x
Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase.
Larson, R. A., Yin, O. Q. P., Hochhaus, A., Saglio, G., Clark, R. E., Nakamae, H., . . . le Coutre, P. D. (2012). Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase.. European journal of clinical pharmacology, 68(5), 723-733. doi:10.1007/s00228-011-1200-7
Release of intracellular calcium primes chronic myeloid leukaemia cells for tyrosine kinase inhibitor-induced apoptosis
Forchap, S. L., Pirmohamed, M., & Clark, R. E. (2012). Release of intracellular calcium primes chronic myeloid leukaemia cells for tyrosine kinase inhibitor-induced apoptosis. LEUKEMIA, 26(3), 490-498. doi:10.1038/leu.2011.231
Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Marin, D., Ibrahim, A. R., Lucas, C., Gerrard, G., Wang, L., Szydlo, R. M., . . . Foroni, L. (2012). Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30(3), 232-238. doi:10.1200/jco.2011.38.6565
Haemopoietic stem cell transplantation in severe autoimmune diseases: Analysis of UK outcomes from the BSBMT database 1997-2009
Snowden, J. A., Pearce, R. M., Lee, J., Kirkland, K., Gilleece, M., Veys, P., . . . Cook, G. (2012). Haemopoietic stem cell transplantation in severe autoimmune diseases: Analysis of UK outcomes from the BSBMT database 1997-2009. British Journal of Haematology, 157, 742-746.
KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib
Marin, D., Gabriel, I. H., Ahmad, S., Foroni, L., de Lavallade, H., Clark, R., . . . Rezvani, K. (2012). KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. LEUKEMIA, 26(2), 296-302. doi:10.1038/leu.2011.180
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.
Larson, R. A., Hochhaus, A., Hughes, T. P., Clark, R. E., Etienne, G., Kim, D. -W., . . . Kantarjian, H. M. (2012). Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.. Leukemia, 26(10), 2197-2203. doi:10.1038/leu.2012.134
Peroxisome proliferator-activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells
Wang, L., Giannoudis, A., Austin, G., & Clark, R. E. (2012). Peroxisome proliferator-activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells. EXPERIMENTAL HEMATOLOGY, 40(10), 811-819. doi:10.1016/j.exphem.2012.05.013
Peroxisome proliferator-activated receptors (PPAR) upregulate the imatinib transporter hOCT1 in chronic myeloid leukaemia
Wang, L., Giannoudis, A., Austin, G., & Clark, R. E. (2012). Peroxisome proliferator-activated receptors (PPAR) upregulate the imatinib transporter hOCT1 in chronic myeloid leukaemia. Experimental Hematology, 40, 811-819.
The predictive value of early molecular response in patients with chronic myeloid leukaemia in chronic phase treated with dasatinib as first line therapy.
Marin, D., Hedgley, C., Clark, R. E., Apperley, J. F., Foroni, L., Milojkovic, D., . . . O'Brien, S. (2012). The predictive value of early molecular response in patients with chronic myeloid leukaemia in chronic phase treated with dasatinib as first line therapy.. Blood, 120, 291-294.
2011
Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed.
Ibrahim, A. R., Clark, R. E., Holyoake, T. L., Byrne, J., Shepherd, P., Apperley, J. F., . . . Marin, D. (2011). Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed.. Haematologica, 96(12), 1779-1782. doi:10.3324/haematol.2011.049759
Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib
Milojkovic, D., Ibrahim, A. R., Foroni, L., Lucas, C., Gerrard, G., Wang, L., . . . Marin, D. (2011). Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib. Blood, 118(21), 1680. doi:10.1182/blood.v118.21.1680.1680
The Predictive Value of Early Molecular Response in Chronic Phase CML Patients Treated with Dasatinib First Line Therapy
Marin, D., Hedgley, C., Clark, R. E., Apperley, J. F., Foroni, L., Milojkovic, D., . . . O'Brien, S. (2011). The Predictive Value of Early Molecular Response in Chronic Phase CML Patients Treated with Dasatinib First Line Therapy. Blood, 118(21), 785. doi:10.1182/blood.v118.21.785.785
Rapid diagnosis of chronic myeloid leukemia by flow cytometric detection of BCR-ABL1 protein
Lucas, C. M., Fagan, J. L., Carter, A., Swale, B., Evans, C., Clark, R. E., & Harris, R. J. (2011). Rapid diagnosis of chronic myeloid leukemia by flow cytometric detection of BCR-ABL1 protein. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 96(7), 1077-1078. doi:10.3324/haematol.2011.043166
Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression
Lucas, C. M., Harris, R. J., Giannoudis, A., Copland, M., Slupsky, J. R., & Clark, R. E. (2011). Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. BLOOD, 117(24), 6660-6668. doi:10.1182/blood-2010-08-304477
Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia.
Schmidt, T., Kharabi Masouleh, B., Loges, S., Cauwenberghs, S., Fraisl, P., Maes, C., . . . Carmeliet, P. (2011). Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia.. Cancer cell, 19(6), 740-753. doi:10.1016/j.ccr.2011.05.007
BCR-ABL peptide vaccination in healthy subjects: immunological responses are equivalent to those in chronic myeloid leukaemia patients.
Rojas, J. M., Knight, K., Watmough, S., Bell, J., Wang, L., Callaghan, T., & Clark, R. E. (2011). BCR-ABL peptide vaccination in healthy subjects: immunological responses are equivalent to those in chronic myeloid leukaemia patients.. Leukemia research, 35(3), 369-372. doi:10.1016/j.leukres.2010.05.028
A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib.
Estabragh, Z. R., Knight, K., Watmough, S. J., Lane, S., Vinjamuri, S., Hart, G., & Clark, R. E. (2011). A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib.. Leukemia research, 35(1), 49-51. doi:10.1016/j.leukres.2010.08.020
2010
EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.
Daghistani, M., Marin, D., Khorashad, J. S., Wang, L., May, P. C., Paliompeis, C., . . . Reid, A. G. (2010). EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.. Blood, 116(26), 6014-6017. doi:10.1182/blood-2010-01-264234
Naturally occurring CD4+ CD25+ FOXP3+ T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive.
Rojas, J. M., Wang, L., Owen, S., Knight, K., Watmough, S. J., & Clark, R. E. (2010). Naturally occurring CD4+ CD25+ FOXP3+ T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive.. Experimental hematology, 38(12), 1209-1218. doi:10.1016/j.exphem.2010.09.004
Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study.
Giles, F. J., Rosti, G., Beris, P., Clark, R. E., le Coutre, P., Mahon, F. -X., . . . Saglio, G. (2010). Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study.. Expert review of hematology, 3(6), 665-673. doi:10.1586/ehm.10.61
Analysis of BCR-ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype.
Jiang, X., Grant, H., Stebbing, J., Foroni, L., Craddock, C., Griffiths, M., . . . Woolfson, A. (2010). Analysis of BCR-ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype.. Blood, 116(21), 3397. doi:10.1182/blood.v116.21.3397.3397
KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib
Gabriel, I. H., Marin, D., Ahmad, S., Foroni, L., de Lavallade, H., Clark, R. E., . . . Rezvani, K. (2010). KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib. Blood, 116(21), 888. doi:10.1182/blood.v116.21.888.888
Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.
Chakraverty, R., Orti, G., Roughton, M., Shen, J., Fielding, A., Kottaridis, P., . . . Mackinnon, S. (2010). Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.. Blood, 116(16), 3080-3088. doi:10.1182/blood-2010-05-286856
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Saglio, G., Kim, D. -W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., . . . ENESTnd Investigators. (2010). Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.. The New England journal of medicine, 362(24), 2251-2259. doi:10.1056/nejmoa0912614
High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression.
Boultwood, J., Perry, J., Zaman, R., Fernandez-Santamaria, C., Littlewood, T., Kusec, R., . . . Wainscoat, J. S. (2010). High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression.. Leukemia, 24(6), 1139-1145. doi:10.1038/leu.2010.65
Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography
Davies, A., Hayes, A. K., Knight, K., Watmough, S. J., Pirmohamed, M., & Clark, R. E. (2010). Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography. LEUKEMIA RESEARCH, 34(6), 702-707. doi:10.1016/j.leukres.2009.11.009
European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy.
Burnett, A. K., Russell, N. H., Kell, J., Dennis, M., Milligan, D., Paolini, S., . . . Hills, R. K. (2010). European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28(14), 2389-2395. doi:10.1200/jco.2009.26.4242
BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia
Lucas, C. M., Harris, R. J., Giannoudis, A., Knight, K., Watmough, S. J., & Clark, R. E. (2010). BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 149(3), 458-460. doi:10.1111/j.1365-2141.2009.08066.x
A genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers.
Dunwell, T., Hesson, L., Rauch, T. A., Wang, L., Clark, R. E., Dallol, A., . . . Latif, F. (2010). A genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers.. Molecular cancer, 9, 44. doi:10.1186/1476-4598-9-44
A Genome-wide screen identifies novel frequently methylated genes in leukemia and genes associated with clinical outcome in chronic myeloid leukaemia
Dunwell, T., Hesson, L., Rauch, T., Wang, L., Clark, R. E., Dallol, A., . . . Latif, F. (2010). A Genome-wide screen identifies novel frequently methylated genes in leukemia and genes associated with clinical outcome in chronic myeloid leukaemia. Molecular Cancer, 9, 44-55.
Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype
Grant, H., Jiang, X., Stebbing, J., Foroni, L., Craddock, C., Griffiths, M., . . . Woolfson, A. (2010). Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype. LEUKEMIA, 24(10), 1817-1821. doi:10.1038/leu.2010.179
Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles.
Shaw, B. E., Mayor, N. P., Russell, N. H., Apperley, J. F., Clark, R. E., Cornish, J., . . . Madrigal, J. A. (2010). Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles.. Leukemia, 24(1), 58-65. doi:10.1038/leu.2009.239
EVI-1 oncogene expression predicts survival in chronic phase CML patients resistant to imatinib
Daghistani, M., Marin, D., Khorashad, J. S., May, P. C., Paliompeis, C., Milojkovic, D., . . . Reid, A. G. (2010). EVI-1 oncogene expression predicts survival in chronic phase CML patients resistant to imatinib. Blood, 116, 6014-6017.
Naturally occurring CD4+ CD25+ FOXP3+ T regulatory cells are increased in chronic myeloid leukaemia patients with high BCR-ABL transcripts and can suppress anti-BCR-ABL responses
Rojas, J. M., Wang, L. H., Owen, S., Knight, K., Watmough, S., & Clark, R. E. (2010). Naturally occurring CD4+ CD25+ FOXP3+ T regulatory cells are increased in chronic myeloid leukaemia patients with high BCR-ABL transcripts and can suppress anti-BCR-ABL responses. Experimental Hematology, 38, 1209-1218.
Nilotinib is superior to imatinib as first line therapy of chronic myeloid leukemia (CML): the ENESTnd study as a landmark on the path to cure in CML
Giles, F. J., Rosti, G., Beris, P., Clark, R. E., le Coutre, P., Mahon, F. -X., . . . Saglio, G. (2010). Nilotinib is superior to imatinib as first line therapy of chronic myeloid leukemia (CML): the ENESTnd study as a landmark on the path to cure in CML. Expert Reviews in Haematology, 3, 665-673.
THE PRE-TREATMENT LEVELS OF PROTEIN PHOSPHATASE 2A (PP2A) AND ITS INHIBITOR SET CAN PREDICT PATIENTS DESTINED TO PROGRESS TO BLAST CRISIS OF CML
Lucas, C., Harris, R. J., Giannoudis, A., & Clark, R. (2010). THE PRE-TREATMENT LEVELS OF PROTEIN PHOSPHATASE 2A (PP2A) AND ITS INHIBITOR SET CAN PREDICT PATIENTS DESTINED TO PROGRESS TO BLAST CRISIS OF CML. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95, 338. Retrieved from https://www.webofscience.com/
The pCrKL/CrKL ratio at initial diagnosis is predictive of treatment outcome in chronic myeloid leukaemia
Lucas, C. M., Harris, R. J., Giannoudis, A., Knight, K., Watmough, S. J., & Clark, R. E. (2010). The pCrKL/CrKL ratio at initial diagnosis is predictive of treatment outcome in chronic myeloid leukaemia. British Journal of Haematology, 149, 158-160.
2009
Chronic myeloid leukemia patients with the e13a2 <i>BCR</i>-<i>ABL</i> fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript
Lucas, C. M., Harris, R. J., Giannoudis, A., Davies, A., Knight, K., Watmough, S. J., . . . Clark, R. E. (2009). Chronic myeloid leukemia patients with the e13a2 <i>BCR</i>-<i>ABL</i> fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 94(10), 1362-1367. doi:10.3324/haematol.2009.009134
Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission.
Patel, B., Kirkland, K. E., Szydlo, R., Pearce, R. M., Clark, R. E., Craddock, C., . . . Marks, D. I. (2009). Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission.. Haematologica, 94(10), 1399-1406. doi:10.3324/haematol.2009.008649
Facts and uncertainties in monitoring treatment response in chronic myeloid leukaemia.
Clark, R. E. (2009). Facts and uncertainties in monitoring treatment response in chronic myeloid leukaemia.. Leukemia research, 33(9), 1151-1155. doi:10.1016/j.leukres.2009.04.001
Soluble HLA/peptide monomers cross-linked with co-stimulatory antibodies onto a streptavidin core molecule efficiently stimulate antigen-specific T cell responses.
Rusakiewicz, S., Aubert, G., Clark, R. E., Madrigal, A. J., Dodi, A. I., & Travers, P. J. (2009). Soluble HLA/peptide monomers cross-linked with co-stimulatory antibodies onto a streptavidin core molecule efficiently stimulate antigen-specific T cell responses.. Cancer immunology, immunotherapy : CII, 58(9), 1459-1470. doi:10.1007/s00262-009-0711-x
Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable?
Riley, C. L., Mathieu, M. G., Clark, R. E., McArdle, S. E. B., & Rees, R. C. (2009). Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable?. Cancer immunology, immunotherapy : CII, 58(9), 1489-1499. doi:10.1007/s00262-009-0675-x
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.
Grimwade, D., Jovanovic, J. V., Hills, R. K., Nugent, E. A., Patel, Y., Flora, R., . . . Burnett, A. K. (2009). Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27(22), 3650-3658. doi:10.1200/jco.2008.20.1533
T cell function in chronic myeloid leukemia and its treatment with tyrosine kinase inhibitors--clues from and for sarcoidosis.
Punekar, M., Thachil, J., Salim, R., Watmough, S., & Clark, R. E. (2009). T cell function in chronic myeloid leukemia and its treatment with tyrosine kinase inhibitors--clues from and for sarcoidosis.. Leukemia research, 33(7), e91-e92. doi:10.1016/j.leukres.2008.11.032
A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response.
Drummond, M. W., Heaney, N., Kaeda, J., Nicolini, F. E., Clark, R. E., Wilson, G., . . . Holyoake, T. L. (2009). A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response.. Leukemia, 23(6), 1199-1201. doi:10.1038/leu.2009.43
Nilotinib concentration in cell lines and primary CD34<SUP>+</SUP> chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters
Davies, A., Jordanides, N. E., Giannoudis, A., Lucas, C. M., Hatziieremia, S., Harris, R. J., . . . Mountford, J. C. (2009). Nilotinib concentration in cell lines and primary CD34<SUP>+</SUP> chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. LEUKEMIA, 23(11), 1999-2006. doi:10.1038/leu.2009.166
2008
Nilotinib concentration in Cell Lines and CML CD34+ Cells Is Not Mediated by Active Uptake or Efflux by Major Drug Transporters
Mountford, J., Davies, A., Jordanides, N. E., Giannoudis, A., Lucas, C. M., Hatziieremia, S., . . . Clark, R. E. (2008). Nilotinib concentration in Cell Lines and CML CD34+ Cells Is Not Mediated by Active Uptake or Efflux by Major Drug Transporters. Blood, 112(11), 3205. doi:10.1182/blood.v112.11.3205.3205
Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia
Giannoudis, A., Davies, A., Lucas, C. M., Harris, R. J., Pirmohamed, M., & Clark, R. E. (2008). Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. BLOOD, 112(8), 3348-3354. doi:10.1182/blood-2007-10-116236
The harvest and use of autologous back-up grafts for graft failure or severe GVHD after allogeneic hematopoietic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation.
Stelljes, M., van Biezen, A., Slavin, S., Olavarria, E., Clark, R. E., Nagler, A., . . . complications subcommittee of the Chronic Leukemia Working Party. (2008). The harvest and use of autologous back-up grafts for graft failure or severe GVHD after allogeneic hematopoietic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation.. Bone marrow transplantation, 42(11), 739-742. doi:10.1038/bmt.2008.254
Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia
Clark, R. E., Davies, A., Pirmohamed, M., & Giannoudis, A. (2008). Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. LEUKEMIA & LYMPHOMA, 49(4), 639-642. doi:10.1080/10428190701858823
Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia
Wang, L., Giannoudis, A., Lane, S., Williamson, P., Pirmohamed, M., & Clark, R. E. (2008). Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. CLINICAL PHARMACOLOGY & THERAPEUTICS, 83(2), 258-264. doi:10.1038/sj.clpt.6100268
A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials
Lucas, C. M., Wang, L., Austin, G. M., Knight, K., Watmough, S. J., Shwe, K. H., . . . Clark, R. E. (2008). A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. LEUKEMIA, 22(10), 1963-1966. doi:10.1038/leu.2008.225
Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia
Wang, L., Giannoudis, A., Lane, S., Williamson, P., Pirmohamed, M., & Clark, R. E. (2008). Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clinical Pharmacology and Therapeutics, 83(2), 258-264. doi:10.1038/sj.clpt.6100268
Immunotherapy in chronic myeloid leukemia
Clark, R. E. (2008). Immunotherapy in chronic myeloid leukemia. In Chronic Myeloproliferative Disorders (pp. 118-125).
2007
Evidence that a BCR-ABL fusion peptide does not induce lymphocyte proliferation or cytokine production in vitro.
Abu-Eisha, H. M., Butt, N. M., Clark, R. E., Christmas, S. E., & Christmas, S. E. (2007). Evidence that a BCR-ABL fusion peptide does not induce lymphocyte proliferation or cytokine production in vitro.. Leukemia research, 31(12), 1675-1681. doi:10.1016/j.leukres.2007.01.007
Characterisation of Nilotinib Transport in Chronic Myeloid Leukaemia Cells.
Davies, A., Giannoudis, A., Lucas, C. M., Harris, R. J., Manley, P. W., Pirmohamed, M., & Clark, R. E. (2007). Characterisation of Nilotinib Transport in Chronic Myeloid Leukaemia Cells.. Blood, 110(11), 2364. doi:10.1182/blood.v110.11.2364.2364
Unlike imatinib, dasatinib uptake into chronic myeloid leukaemia cells is independent of hOCT1 expression
Giannoudis, A., Davies, A., Lucas, C. M., Harris, R. J., Pirmohamed, M., & Clark, R. E. (2007). Unlike imatinib, dasatinib uptake into chronic myeloid leukaemia cells is independent of hOCT1 expression. In BLOOD Vol. 110 (pp. 1013A-1014A). doi:10.1182/blood.V110.11.3458.3458
Immunotherapeutic strategies in chronic myeloid leukemia.
Clark, R. E. (2007). Immunotherapeutic strategies in chronic myeloid leukemia.. Current hematologic malignancy reports, 2(2), 89-94. doi:10.1007/s11899-007-0013-3
Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study.
Rojas, J. M., Knight, K., Wang, L., & Clark, R. E. (2007). Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study.. Leukemia, 21(11), 2287-2295. doi:10.1038/sj.leu.2404858
Dasatinib: a new therapy for myeloproliferative disorders
Clark, R. E. (2007). Dasatinib: a new therapy for myeloproliferative disorders. Myeloproliferative Disorders in Practice, 1, 3-5.
Definition of the breakpoint fusion peptides for HLA-B8 as well as HLA-A3 in CML cells.
Dodi, I. A., Rusakiewicz, S., Aubert, G., Clark, R. E., Creaser, C., Bonner, P., . . . Madrigal, J. A. (2007). Definition of the breakpoint fusion peptides for HLA-B8 as well as HLA-A3 in CML cells.. In J. A. Hansen (Ed.), Immunobiology of the Human MHC; proceedings of 13th International workshop and congress. Vol II. (pp. 275-280). Seattle: International Histocompatibily Workshop Group press.
Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group.
Ruutu, T., Barosi, G., Benjamin, R. J., Clark, R. E., George, J. N., Gratwohl, A., . . . European LeukemiaNet. (2007). Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group.. Haematologica, 92(1), 95-100. doi:10.3324/haematol.10699
2006
Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database.
Saccardi, R., Kozak, T., Bocelli-Tyndall, C., Fassas, A., Kazis, A., Havrdova, E., . . . Autoimmune Diseases Working Party of EBMT. (2006). Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database.. Multiple sclerosis (Houndmills, Basingstoke, England), 12(6), 814-823. doi:10.1177/1352458506071301
Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter.
Clark, R., Kerr, I. D., & Callaghan, R. (2006). Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter.. British journal of pharmacology, 149(5), 506-515. doi:10.1038/sj.bjp.0706904
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.
Knapper, S., Burnett, A. K., Littlewood, T., Kell, W. J., Agrawal, S., Chopra, R., . . . Small, D. (2006). A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.. Blood, 108(10), 3262-3270. doi:10.1182/blood-2006-04-015560
Clinical and functional evidence that drug transporter expression dictates the response to imatinib in chronic myeloid leukaemia.
Wang, L., Giannoudis, A., Lane, S., Williamson, P. R., Pirmohamed, M., & Clark, R. E. (2006). Clinical and functional evidence that drug transporter expression dictates the response to imatinib in chronic myeloid leukaemia.. In BLOOD Vol. 108 (pp. 608A-609A). doi:10.1182/blood.V108.11.2145.2145
The outcome of sibling and unrelated donor allogeneic stem cell transplantation in adult patients with acute myeloid leukemia in first remission who were initially refractory to first induction chemotherapy.
Cook, G., Clark, R. E., Crawley, C., Mackinnon, S., Russell, N., Thomson, K., . . . Marks, D. I. (2006). The outcome of sibling and unrelated donor allogeneic stem cell transplantation in adult patients with acute myeloid leukemia in first remission who were initially refractory to first induction chemotherapy.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 12(3), 293-300. doi:10.1016/j.bbmt.2005.10.019
The role of serial <i>BCR-ABL</i> transcript monitoring in predicting the emergence of <i>BCR-ABL</i> kinase mutations in imatinib-treated patients with chronic myeloid leukemia
Wang, L. H., Knight, K., Lucas, C., & Clark, R. E. (2006). The role of serial <i>BCR-ABL</i> transcript monitoring in predicting the emergence of <i>BCR-ABL</i> kinase mutations in imatinib-treated patients with chronic myeloid leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 91(2), 235-239. Retrieved from https://www.webofscience.com/
2005
Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the Clinical Trials Committee of the British Society of Blood & Marrow Transplantation (BSBMT).
Cummins, M., Cwynarski, K., Marktel, S., Dazzi, F., Cavenagh, J., Clark, R. E., . . . Clinical Trials Committee British Society of Blood & Marrow Transplantation (BSBMT). (2005). Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the Clinical Trials Committee of the British Society of Blood & Marrow Transplantation (BSBMT).. Bone marrow transplantation, 36(12), 1065-1069. doi:10.1038/sj.bmt.1705180
Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients
Butt, N. M., Rojas, J. M., Wang, L., Christmas, S. E., Abu-Eisha, H. M., & Clark, R. E. (2005). Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients. Haematologica, 90(10), 1315-1323. Retrieved from http://www.haematologica.org/journal/2005/901315.pdf
Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects.
Butt, N. M., Rojas, J. M., Wang, L., Christmas, S. E., Abu-Eisha, H. M., & Clark, R. E. (2005). Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects.. Haematologica, 90(10), 1315-1323.
hOCT 1 and resistance to imatinib
Crossman, L. C., Druker, B. J., & Deininger, M. W. N. (2005). hOCT 1 and resistance to imatinib. BLOOD, 106(3), 1133-1134. doi:10.1182/blood-2005-02-0694
Ancestim associated with Filgrastim and/or chemotherapy can improve blood progenitor yields in patients who previously failed mobilisation.
Mijovic, A., Russell, N., Clark, R. E., Morris, T. C. M., Browne, P., Crown, J., . . . Mufti, G. J. (2005). Ancestim associated with Filgrastim and/or chemotherapy can improve blood progenitor yields in patients who previously failed mobilisation.. Bone marrow transplantation, 35(10), 1019. doi:10.1038/sj.bmt.1704950
The immune response to chronic myeloid leukaemia
Clark, R. E. (2005). The immune response to chronic myeloid leukaemia. In R. F. Romero (Ed.), Focus on Leukemia Research (pp. 27-60). New York: Nova Science Publishers, Inc.
Uncertainties in the use of imatinib in chronic myeloid leukaemia
Clark, R. E., & Wang, L. (2005). Uncertainties in the use of imatinib in chronic myeloid leukaemia. British Journal of Cancer Management, 1, 11-14.
2004
Active transport of imatinib into and out of cells: implications for drug resistance
Thomas, J., Wang, L. H., Clark, R. E., & Pirmohamed, M. (2004). Active transport of imatinib into and out of cells: implications for drug resistance. BLOOD, 104(12), 3739-3745. doi:10.1182/blood-2003-12-4276
A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma.
Cook, G., Clark, R. E., Morris, T. C. M., Robertson, M., Lucie, N. P., Anderson, S., . . . Franklin, I. M. (2004). A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma.. British journal of haematology, 126(6), 792-798. doi:10.1111/j.1365-2141.2004.05127.x
Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib.
Heartin, E., Walkinshaw, S., & Clark, R. E. (2004). Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib.. Leukemia & lymphoma, 45(6), 1307-1308. doi:10.1080/10428190310001645195
Dendritic cells become BCR-ABL negative in chronic myeloid leukaemia patients successfully treated with imatinib.
Wang, L., Butt, N. M., Atherton, M. G., & Clark, R. E. (2004). Dendritic cells become BCR-ABL negative in chronic myeloid leukaemia patients successfully treated with imatinib.. Leukemia, 18(5), 1025-1027. doi:10.1038/sj.leu.2403342
BCR-ABL-specific T cells can be detected in healthy donors and in chronic myeloid leukemia patients following allogeneic stem cell transplantation.
Butt, N. M., Wang, L., Abu-Eisha, H. M., Christmas, S. E., & Clark, R. E. (2004). BCR-ABL-specific T cells can be detected in healthy donors and in chronic myeloid leukemia patients following allogeneic stem cell transplantation.. Blood, 103(8), 3245. doi:10.1182/blood-2003-11-4086
Active transport of imatinib into and out of cells: implications for drug resistance
Thomas, J., Wang, L., Clark, R. E., & Pirmohamed, M. (2004). Active transport of imatinib into and out of cells: implications for drug resistance. Blood, 104(12), 3739-3745. doi:10.1182/blood-2003-12-4276
2003
A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia.
Kell, W. J., Burnett, A. K., Chopra, R., Yin, J. A. L., Clark, R. E., Rohatiner, A., . . . Milligan, D. W. (2003). A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia.. Blood, 102(13), 4277-4283. doi:10.1182/blood-2003-05-1620
Autografting as a risk factor for persisting iron overload in long-term survivors of acute myeloid leukaemia.
Butt, N. M., & Clark, R. E. (2003). Autografting as a risk factor for persisting iron overload in long-term survivors of acute myeloid leukaemia.. Bone marrow transplantation, 32(9), 909-913. doi:10.1038/sj.bmt.1704244
Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission.
Drummond, M. W., Marin, D., Clark, R. E., Byrne, J. L., Holyoake, T. L., Lennard, A., & United Kingdom Chronic Myeloid Leukaemia (UK CML) Working Party. (2003). Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission.. British journal of haematology, 123(3), 479-483. doi:10.1046/j.1365-2141.2003.04599.x
Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow.
Gorin, N. C., Labopin, M., Rocha, V., Arcese, W., Beksac, M., Gluckman, E., . . . European Cooperative Group for Blood and Marrow Transplantation Acute Leukemia Working Party. (2003). Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow.. Blood, 102(8), 3043-3051. doi:10.1182/blood-2003-03-0665
BCR-ABL with an e6a2 fusion in a CML patient diagnosed in blast crisis.
Schultheis, B., Wang, L., Clark, R. E., & Melo, J. V. (2003). BCR-ABL with an e6a2 fusion in a CML patient diagnosed in blast crisis.. Leukemia, 17(10), 2054-2055. doi:10.1038/sj.leu.2403079
Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions.
Huntly, B. J. P., Guilhot, F., Reid, A. G., Vassiliou, G., Hennig, E., Franke, C., . . . Deininger, M. W. N. (2003). Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions.. Blood, 102(6), 2205-2212. doi:10.1182/blood-2002-09-2763
CD34 positive selection as prophylaxis against graft versus host disease in allogeneic peripheral blood stem cell transplantation.
Butt, N. M., McGinnity, N., & Clark, R. E. (2003). CD34 positive selection as prophylaxis against graft versus host disease in allogeneic peripheral blood stem cell transplantation.. Leukemia & lymphoma, 44(9), 1509-1513. doi:10.1080/1042819031000083019
Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
Olavarria, E., Ottmann, O. G., Deininger, M., Clark, R. E., Bandini, G., Byrne, J., . . . Chronic Leukaemia Working Party of the European Group of Bone and Marrow Transplantation (EBMT). (2003). Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.. Leukemia, 17(9), 1707-1712. doi:10.1038/sj.leu.2403068
A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial).
Giles, F. J., Miller, C. B., Hurd, D. D., Wingard, J. R., Fleming, T. R., Sonis, S. T., . . . PROMPT-CT Trial Investigators. (2003). A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial).. Leukemia & lymphoma, 44(7), 1165-1172. doi:10.1080/1042819031000079159
CpG oligodeoxynucleotide 5mer-induced apoptosis in MOLT-4 leukaemia cells does not require caspase 3 or new protein synthesis
Tidd, D. M., Broughton, C. M., & Clark, R. E. (2003). CpG oligodeoxynucleotide 5mer-induced apoptosis in MOLT-4 leukaemia cells does not require caspase 3 or new protein synthesis. NUCLEIC ACIDS RESEARCH, 31(9), 2297-2304. doi:10.1093/nar/gkg334
A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation.
Papas, A. S., Clark, R. E., Martuscelli, G., O'Loughlin, K. T., Johansen, E., & Miller, K. B. (2003). A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation.. Bone marrow transplantation, 31(8), 705-712. doi:10.1038/sj.bmt.1703870
The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia.
Wang, L., Pearson, K., Ferguson, J. E., & Clark, R. E. (2003). The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia.. British journal of haematology, 120(6), 990-999. doi:10.1046/j.1365-2141.2003.04200.x
Successful mobilisation of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukemia patients with imatinib mesylate (Gleevec®)-induced complete cytogenetic remission
Drummond, M. W., Marin, D., Clark, R. E., Byrne, J., Goldman, J. M., Holyoake, T. L., & Lennard, A. (2003). Successful mobilisation of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukemia patients with imatinib mesylate (Gleevec®)-induced complete cytogenetic remission. British Journal of Haematology, 123(3), 479-483.
2002
Chronic lymphocytic leukaemia developing in the course of chronic myeloid leukaemia.
Salim, R., Wang, L., Lin, K., & Clark, R. E. (2002). Chronic lymphocytic leukaemia developing in the course of chronic myeloid leukaemia.. Leukemia & lymphoma, 43(11), 2225-2227. doi:10.1080/1042819021000016140a
Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
Wang, L., Pearson, K., Pillitteri, L., Ferguson, J. E., & Clark, R. E. (2002). Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.. British journal of haematology, 118(3), 771-777. doi:10.1046/j.1365-2141.2002.03705.x
The post-transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukaemia in chronic phase.
Olavarria, E., Reiffers, J., Boque, C., Sureda, A., Meloni, G., Michallet, M., . . . Apperley, J. F. (2002). The post-transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukaemia in chronic phase.. British journal of haematology, 118(3), 762-770. doi:10.1046/j.1365-2141.2002.03600.x
e19a2-positive chronic myeloid leukaemia with BCR exon e16-deleted transcripts.
Wang, L., Seale, J., Woodcock, B. E., & Clark, R. E. (2002). e19a2-positive chronic myeloid leukaemia with BCR exon e16-deleted transcripts.. Leukemia, 16(8), 1562-1563. doi:10.1038/sj.leu.2402600
Not so NICE for CML
Goldman, J., Apperley, J., Clark, R., Green, T., Holyoake, T., O'Brien, S., & Shepherd, P. (2002). Not so NICE for CML. LANCET, 359(9322), 2036. doi:10.1016/S0140-6736(02)08796-2
Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants.
Ljungman, P., de La Camara, R., Milpied, N., Volin, L., Russell, C. A., Crisp, A., . . . Valacyclovir International Bone Marrow Transplant Study Group. (2002). Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants.. Blood, 99(8), 3050-3056. doi:10.1182/blood.v99.8.3050
Bone turnover following autologous transplantation in multiple myeloma.
Clark, R. E., & Fraser, W. D. (2002). Bone turnover following autologous transplantation in multiple myeloma.. Leukemia & lymphoma, 43(3), 511-516. doi:10.1080/10428190290011985
Position paper on imatinib mesylate in chronic myeloid leukaemia
O'Brien, S. G., Rule, S. A. J., Milligan, D. W., Johnson, S., Marcus, R., Goldman, J. M., . . . Smith, G. (2002). Position paper on imatinib mesylate in chronic myeloid leukaemia. British Journal of Haematology, 119, 268-272.
2001
Laparoscopically assisted splenectomy for idiopathic thrombocytopenic purpura in a previously conserved spleen.
Isherwood, P., Hershman, M. J., Hartley, M., & Clark, R. E. (2001). Laparoscopically assisted splenectomy for idiopathic thrombocytopenic purpura in a previously conserved spleen.. Hospital medicine (London, England : 1998), 62(11), 708-709.
Expression of c-myc is not critical for cell proliferation in established human leukemia lines.
Tidd, D. M., Giles, R. V., Broughton, C. M., & Clark, R. E. (2001). Expression of c-myc is not critical for cell proliferation in established human leukemia lines.. BMC molecular biology, 2, 13. doi:10.1186/1471-2199-2-13
Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein.
Clark, R. E., Dodi, I. A., Hill, S. C., Lill, J. R., Aubert, G., Macintyre, A. R., . . . Madrigal, J. A. (2001). Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein.. Blood, 98(10), 2887-2893. doi:10.1182/blood.v98.10.2887
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial.
Goldstone, A. H., Burnett, A. K., Wheatley, K., Smith, A. G., Hutchinson, R. M., Clark, R. E., & Medical Research Council Adult Leukemia Working Party. (2001). Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial.. Blood, 98(5), 1302-1311. doi:10.1182/blood.v98.5.1302
HLA-A3 increases and HLA-DR1 decreases the risk of acute graft-versus-host disease after HLA-matched sibling bone marrow transplantation for chronic myelogenous leukaemia.
Clark, R. E., Hermans, J., Madrigal, A., Nachbaur, D., Kropshofer, G., Gratwohl, A., . . . Chronic Leukaemia Working Party of the European Group of Blood and Bone Marrow Transplantation. (2001). HLA-A3 increases and HLA-DR1 decreases the risk of acute graft-versus-host disease after HLA-matched sibling bone marrow transplantation for chronic myelogenous leukaemia.. British journal of haematology, 114(1), 36-41. doi:10.1046/j.1365-2141.2001.02897.x
High frequency of positive surveillance for cytomegalovirus (CMV) by PCR in allograft recipients at low risk of CMV.
Butt, N. M., & Clark, R. E. (2001). High frequency of positive surveillance for cytomegalovirus (CMV) by PCR in allograft recipients at low risk of CMV.. Bone marrow transplantation, 27(6), 615-619. doi:10.1038/sj.bmt.1702836
BCR-ABL fusion peptides and cytotoxic T cells in chronic myeloid leukaemia.
Clark, R. E., & Christmas, S. E. (2001). BCR-ABL fusion peptides and cytotoxic T cells in chronic myeloid leukaemia.. Leukemia & lymphoma, 42(5), 871-880. doi:10.3109/10428190109097706
Characterisation of HLA-A3 restricted peptide from the BCR-ABL fusion protein of the Philadelphia chromosome using Nano-electrospray ion trap mass spectrometry
Creaser, C. S., Lill, J. R., Bonner, P. L. R., Hill, S. C., Rees, R. C., Christmas, S. E., . . . Madrigal, J. A. (2001). Characterisation of HLA-A3 restricted peptide from the BCR-ABL fusion protein of the Philadelphia chromosome using Nano-electrospray ion trap mass spectrometry. Advances in Mass Spectrometry, 15, 637-638.
Expression of c-myc is not critical for cell proliferation in established human leukemia lines
Tidd, D. M., Giles, R. V., Broughton, C. M., & Clark, R. E. (2001). Expression of c-myc is not critical for cell proliferation in established human leukemia lines. Biomed Central (BMC) Molecular Biology, 2, 13. Retrieved from http://www.biomedcentral.com/1471-2199/2/13/
2000
Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma.
Clark, R. E., Flory, A. J., Ion, E. M., Woodcock, B. E., Durham, B. H., & Fraser, W. D. (2000). Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma.. Blood, 96(8), 2697-2702.
b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia.
Norbury, L. C., Clark, R. E., Christmas, S. E., & Christmas, S. E. (2000). b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia.. British journal of haematology, 109(3), 616-621. doi:10.1046/j.1365-2141.2000.02090.x
Oligodeoxynucleotide 5mers containing a 5′-CpG induce apoptosis through a mitochondrial mechanism in T lymphocytic leukaemia cells
Tidd, D. M., Spiller, D. G., Broughton, C. M., Norbury, L. C., Clark, R. E., & Giles, R. V. (2000). Oligodeoxynucleotide 5mers containing a 5′-CpG induce apoptosis through a mitochondrial mechanism in T lymphocytic leukaemia cells. NUCLEIC ACIDS RESEARCH, 28(11), 2242-2250. doi:10.1093/nar/28.11.2242
Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems.
Clark, R. E. (2000). Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems.. Leukemia, 14(3), 347-355. doi:10.1038/sj.leu.2401677
1999
Clinical use of streptolysin-O to facilitate antisense oligodeoxyribonucleotide delivery for purging autografts in chronic myeloid leukaemia
Clark, R. E., Grzybowski, J., Broughton, C. M., Pender, N. T., Spiller, D. G., Brammer, C. G., . . . Tidd, D. M. (1999). Clinical use of streptolysin-O to facilitate antisense oligodeoxyribonucleotide delivery for purging autografts in chronic myeloid leukaemia. BONE MARROW TRANSPLANTATION, 23(12), 1303-1308. doi:10.1038/sj.bmt.1701801
Chemotherapy-induced acral erythema (CIAE) with bullous reaction.
Azurdia, R. M., Clark, R. E., & Friedmann, P. S. (1999). Chemotherapy-induced acral erythema (CIAE) with bullous reaction.. Clinical and experimental dermatology, 24(2), 64-66. doi:10.1046/j.1365-2230.1999.00419.x
Antisense morpholino oligonucleotide analog induces missplicing of C-myc mRNA.
Giles, R. V., Spiller, D. G., Clark, R. E., & Tidd, D. M. (1999). Antisense morpholino oligonucleotide analog induces missplicing of C-myc mRNA.. Antisense & nucleic acid drug development, 9(2), 213-220. doi:10.1089/oli.1.1999.9.213
Antisense morpholino oligonucleotide analogue induces mis-splicing of c-MYC mRNA
Giles, R. V., Spiller, D. G., Clark, R. E., & Tidd, D. M. (1999). Antisense morpholino oligonucleotide analogue induces mis-splicing of c-MYC mRNA. Antisense & Nucleic Acid Drug Development, 9, 213-220.
Identification of a good c-myc antisense oligodeoxynucleotide target site and the inactivity at this site of novel NCH triplet--targeting ribozymes.
Giles, R. V., Spiller, D. G., Clark, R. E., & Tidd, D. M. (1999). Identification of a good c-myc antisense oligodeoxynucleotide target site and the inactivity at this site of novel NCH triplet--targeting ribozymes.. Nucleosides & nucleotides, 18(9), 1935-1944. doi:10.1080/07328319908044855
1998
Bone-marrow donation by mentally incapable adults.
Clark, R. E. (1998). Bone-marrow donation by mentally incapable adults.. Lancet (London, England), 352(9143), 1847-1848. doi:10.1016/s0140-6736(98)04378-5
Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system.
Clark, R. E., & Brammer, C. G. (1998). Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system.. Bone marrow transplantation, 22(9), 859-863. doi:10.1038/sj.bmt.1701461
Autologous transplantation in chronic myeloid leukaemia using peripheral blood stem cells.
Singer, I. O., Franklin, I. M., Clark, R. E., Chalmers, E. A., Kelsey, S. M., Newland, A. C., . . . Tansey, P. J. (1998). Autologous transplantation in chronic myeloid leukaemia using peripheral blood stem cells.. British journal of haematology, 102(5), 1359-1362. doi:10.1046/j.1365-2141.1998.00897.x
Comparison of a patient-controlled analgesia system with continuous infusion for administration of diamorphine for mucositis.
Pillitteri, L. C., & Clark, R. E. (1998). Comparison of a patient-controlled analgesia system with continuous infusion for administration of diamorphine for mucositis.. Bone marrow transplantation, 22(5), 495-498. doi:10.1038/sj.bmt.1701370
Abnormalities of the ETV6 gene occur in the majority of patients with aberrations of the short arm of chromosome 12: a combined PCR and Southern blotting analysis.
O'Connor, H. E., Butler, T. A., Clark, R., Swanton, S., Harrison, C. J., Secker-Walker, L. M., & Foroni, L. (1998). Abnormalities of the ETV6 gene occur in the majority of patients with aberrations of the short arm of chromosome 12: a combined PCR and Southern blotting analysis.. Leukemia, 12(7), 1099-1106. doi:10.1038/sj.leu.2401070
Improving the Intracellular Delivery and Molecular Efficacy of Antisense Oligonucleotides in Chronic Myeloid Leukemia Cells: A Comparison of Streptolysin-O Permeabilization, Electroporation, and Lipophilic Conjugation
Spiller, D. G., Giles, R. V., Grzybowski, J., Tidd, D. M., & Clark, R. E. (1998). Improving the Intracellular Delivery and Molecular Efficacy of Antisense Oligonucleotides in Chronic Myeloid Leukemia Cells: A Comparison of Streptolysin-O Permeabilization, Electroporation, and Lipophilic Conjugation. Blood, 91(12), 4738-4746. doi:10.1182/blood.v91.12.4738
Improving the intracellular delivery and molecular efficacy of antisense oligonucleotides in chronic myeloid leukemia cells: a comparison of streptolysin-O permeabilization, electroporation, and lipophilic conjugation.
Spiller, D. G., Giles, R. V., Grzybowski, J., Tidd, D. M., & Clark, R. E. (1998). Improving the intracellular delivery and molecular efficacy of antisense oligonucleotides in chronic myeloid leukemia cells: a comparison of streptolysin-O permeabilization, electroporation, and lipophilic conjugation.. Blood, 91(12), 4738-4746.
Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells.
Giles, R. V., Spiller, D. G., Grzybowski, J., Clark, R. E., Nicklin, P., & Tidd, D. M. (1998). Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells.. Nucleic acids research, 26(7), 1567-1575. doi:10.1093/nar/26.7.1567
Maximising antisense oligonucleotide efficacy: Selecting optimal structures for Streptolysin O delivery into human leukaemia cells
Giles, R. V., Spiller, D. G., Grzybowski, J., Clark, R. E., Nicklin, P., & Tidd, D. M. (1998). Maximising antisense oligonucleotide efficacy: Selecting optimal structures for Streptolysin O delivery into human leukaemia cells. Nucleic Acids Research, 26, 1567-1575.
The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog-mediated biologic responses
Spiller, D. G., Giles, R. V., Broughton, C. M., Grzybowski, J., Ruddell, C. J., Tidd, D. M., & Clark, R. E. (1998). The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog-mediated biologic responses. ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 8(4), 281-293. doi:10.1089/oli.1.1998.8.281
1997
Improving the molecular efficacy of antisense oligonucleotider (ODN) in chronic myeloid leukaemia
Clark, R. E., Grjsybowski, J., Giles, R. V., Spiller, D. G., & Tidd, D. M. (1997). Improving the molecular efficacy of antisense oligonucleotider (ODN) in chronic myeloid leukaemia. Experimental Hematology, 25(8), 892.
Transplantation of antisense oligonucleotide (odn) purged autografts in chronic myeloid leukaemia (cml)
Clark, R. E. (1997). Transplantation of antisense oligonucleotide (odn) purged autografts in chronic myeloid leukaemia (cml). Experimental Hematology, 25(8), 781.
Preclinical studies of streptolysin-O in enhancing antisense oligonucleotide uptake in harvests from chronic myeloid leukaemia patients
Broughton, C. M., Spiller, D. G., Pender, N., Komorovskaya, M., Grzybowski, J., Giles, R. V., . . . Clark, R. E. (1997). Preclinical studies of streptolysin-O in enhancing antisense oligonucleotide uptake in harvests from chronic myeloid leukaemia patients. LEUKEMIA, 11(9), 1435-1441. doi:10.1038/sj.leu.2400774
European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Devergie, A., Apperley, J. F., Labopin, M., Madrigal, A., Jacobsen, N., Carreras, E., . . . Gratwohl, A. (1997). European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.. Bone marrow transplantation, 20(1), 11-19. doi:10.1038/sj.bmt.1700844
Molecular status of individual CFU-GM colonies derived from chemotherapy-mobilised peripheral blood stem cells in chronic myeloid leukaemia
Broughton, C. M., Sherrington, P., Pender, N. T., & Clark, R. E. (1997). Molecular status of individual CFU-GM colonies derived from chemotherapy-mobilised peripheral blood stem cells in chronic myeloid leukaemia. GENES CHROMOSOMES & CANCER, 18(4), 292-298. doi:3.0.CO;2-W">10.1002/(SICI)1098-2264(199704)18:4<292::AID-GCC7>3.0.CO;2-W
Molecular status of individual CFU-GM colonies derived from chemotherapy-mobilised peripheral blood stem cells in chronic myeloid leukaemia.
Broughton, C. M., Sherrington, P., Pender, N. T., & Clark, R. E. (1997). Molecular status of individual CFU-GM colonies derived from chemotherapy-mobilised peripheral blood stem cells in chronic myeloid leukaemia.. Genes, chromosomes & cancer, 18(4), 292-298. doi:3.0.co;2-w">10.1002/(sici)1098-2264(199704)18:4<292::aid-gcc7>3.0.co;2-w
Treatment of chronic myeloid leukaemia in first chronic phase with idarubicin and cytarabine: mobilization of Philadelphia-negative peripheral blood stem cells.
Chalmers, E. A., Franklin, I. M., Kelsey, S. M., Newland, A. C., Clark, R. E., Sproul, A. M., . . . Tansey, P. (1997). Treatment of chronic myeloid leukaemia in first chronic phase with idarubicin and cytarabine: mobilization of Philadelphia-negative peripheral blood stem cells.. British journal of haematology, 96(3), 627-634. doi:10.1046/j.1365-2141.1997.d01-2058.x
Bone marrow effects of anticancer therapy
Clark, R. E. (1997). Bone marrow effects of anticancer therapy. In J. W. Sweetenham, & C. J. Williams (Eds.), Supportive care of the cancer patient (pp. 3-15). London: Edward Arnold.
Stem cell transplantation
Clark, R. E. (1997). Stem cell transplantation. In F. E. Johnson, & K. S. Virgo (Eds.), Cancer patient follow-up (pp. 504-507). St Louis: Mosby Inc..
The follow-up of patients with lymphoma
Clark, R. E. (1997). The follow-up of patients with lymphoma. In F. E. Johnson, & K. S. Virgo (Eds.), Cancer patient follow-up (pp. 480-483). St Louis: Mosby Inc..
1996
The influence of class II HLA type on the lymphoproliferative response of normal donors to a bcr-abl fusion peptide.
MacIntyre, A. R., Christmas, S. E., & Clark, R. E. (1996). The influence of class II HLA type on the lymphoproliferative response of normal donors to a bcr-abl fusion peptide.. Experimental hematology, 24(11), 1307-1311.
1995
Optimization of antisense oligodeoxynucleotide structure for targeting bcr-abl mRNA.
Giles, R. V., Spiller, D. G., Green, J. A., Clark, R. E., & Tidd, D. M. (1995). Optimization of antisense oligodeoxynucleotide structure for targeting bcr-abl mRNA.. Blood, 86(2), 744-754.
FMS mutations in patients following cytotoxic therapy for lymphoma
Baker, A., Cachia, P. G., Ridge, S. A., McGlynn, H., Clark, R. E., Whittaker, J. A., . . . Padua, R. A. (1995). FMS mutations in patients following cytotoxic therapy for lymphoma. Leukaemia Research, 19, 309-318.
Poor cellular uptake of antisense oligodeoxynucleotides: an obstacle to their use in chronic myeloid leukaemia.
Clark, R. E. (1995). Poor cellular uptake of antisense oligodeoxynucleotides: an obstacle to their use in chronic myeloid leukaemia.. Leukemia & lymphoma, 19(3-4), 189-195. doi:10.3109/10428199509107888
Psychosocial morbidity following bone marrow transplantation is related to previous experience of intensive therapy
Leigh, S., Burns, R., Wilson, K., & Clark, R. E. (1995). Psychosocial morbidity following bone marrow transplantation is related to previous experience of intensive therapy. Bone Marrow Transplantation, 13, 635-640.
Psychosocial morbidity in bone marrow transplant recipients: a prospective study.
Leigh, S., Wilson, K. C., Burns, R., & Clark, R. E. (1995). Psychosocial morbidity in bone marrow transplant recipients: a prospective study.. Bone marrow transplantation, 16(5), 635-640.
Severe hypophosphataemia during stem cell harvesting in chronic myeloid leukaemia.
Clark, R. E., & Lee, E. S. (1995). Severe hypophosphataemia during stem cell harvesting in chronic myeloid leukaemia.. British journal of haematology, 90(2), 450-452. doi:10.1111/j.1365-2141.1995.tb05172.x
Transplantation of T-lymphocyte depleted marrow with an addback of T cells.
Clark, R. E., & Pender, N. (1995). Transplantation of T-lymphocyte depleted marrow with an addback of T cells.. Hematological oncology, 13(4), 219-224. doi:10.1002/hon.2900130406
Transplantation of T-lymphocyte depleted marrow with an addback of T cells: Control of graft-versus-host disease with a high relapse rate
Clark, R. E., & Pender, N. (1995). Transplantation of T-lymphocyte depleted marrow with an addback of T cells: Control of graft-versus-host disease with a high relapse rate. Haematological Oncology, 13, 219-224.
1994
Delayed commencement of granulocyte colony-stimulating factor following autologous bone marrow transplantation accelerates neutrophil recovery and is cost-effective.
Clark, R. E., Shlebak, A. A., & Creagh, M. D. (1994). Delayed commencement of granulocyte colony-stimulating factor following autologous bone marrow transplantation accelerates neutrophil recovery and is cost-effective.. Leukemia & lymphoma, 16(1-2), 141-146. doi:10.3109/10428199409114151
Mobilisation of Ph-negative peripheral blood stem cells in CML with Idarubicin and Cytarabine
Chalmers, E. A., Franklin, I. M., Kelsey, S., Clark, R. E., Sproul, A. M., Goldstone, A. H., . . . Tansey, P. (1994). Mobilisation of Ph-negative peripheral blood stem cells in CML with Idarubicin and Cytarabine. Bone Marrow Transplantation, 14, Su, 38-41.
The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with metastatic or high-risk primary breast cancer. National Surgical Adjuvant Breast and Bowel Project.
Mamounas, E. P., Anderson, S., Wickerham, D. L., Clark, R., Stoller, R., Hamm, J. T., . . . Bornstein, R. (1994). The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with metastatic or high-risk primary breast cancer. National Surgical Adjuvant Breast and Bowel Project.. American journal of clinical oncology, 17(5), 374-382. doi:10.1097/00000421-199410000-00002
Thrombotic microangiopathy following bone marrow transplantation.
Pettitt, A. R., & Clark, R. E. (1994). Thrombotic microangiopathy following bone marrow transplantation.. Bone marrow transplantation, 14(4), 495-504.
Vogt-Koyanagi-Harada syndrome complicating allogeneic bone marrow transplantation.
Pettitt, A. R., Neoh, C., Wong, S. H., & Clark, R. E. (1994). Vogt-Koyanagi-Harada syndrome complicating allogeneic bone marrow transplantation.. Bone marrow transplantation, 13(2), 225-227.
1993
Clonal haemopoiesis following cytotoxic therapy for lymphoma.
Cachia, P. G., Culligan, D. J., Clark, R. E., Whittaker, J. A., Jacobs, A., & Padua, R. A. (1993). Clonal haemopoiesis following cytotoxic therapy for lymphoma.. Leukemia, 7(6), 795-800.
Long-term bone marrow cultures established from bone marrow transplant recipients.
Treweeke, A. T., Hampson, J., & Clark, R. E. (1993). Long-term bone marrow cultures established from bone marrow transplant recipients.. Leukemia & lymphoma, 12(1-2), 117-122. doi:10.3109/10428199309059579
1992
Chromosome aberrations following cytotoxic therapy in patients in complete remission from lymphoma.
White, A. D., Jones, B. M., Clark, R. E., & Jacobs, A. (1992). Chromosome aberrations following cytotoxic therapy in patients in complete remission from lymphoma.. Carcinogenesis, 13(7), 1095-1099. doi:10.1093/carcin/13.7.1095
Thrombotic thrombocytopenic purpura due to rifampicin.
Fahal, I. H., Williams, P. S., Clark, R. E., & Bell, G. M. (1992). Thrombotic thrombocytopenic purpura due to rifampicin.. BMJ (Clinical research ed.), 304(6831), 882. doi:10.1136/bmj.304.6831.882
Isochromosome (6p) in Waldenstrom's macroglobulinemia.
White, A. D., Clark, R. E., & Jacobs, A. (1992). Isochromosome (6p) in Waldenstrom's macroglobulinemia.. Cancer genetics and cytogenetics, 58(1), 89-91. doi:10.1016/0165-4608(92)90141-t
1990
Haemopoietic and molecular abnormalities in the myelodysplastic syndrome
Jacobs, A., Carter, G., Ridge, S., Hughes, D., Geddes, D., Bowen, D., . . . Padua, R. A. (1990). Haemopoietic and molecular abnormalities in the myelodysplastic syndrome. In L. Sachs (Ed.), Molecular Biology of Haemopoiesis (pp. 571-577). Andover UK: Intercept Ltd.
RAS mutations in patients following cytotoxic therapy for lymphoma.
Carter, G., Hughes, D. C., Clark, R. E., McCormick, F., Jacobs, A., Whittaker, J. A., & Padua, R. A. (1990). RAS mutations in patients following cytotoxic therapy for lymphoma.. Oncogene, 5(3), 411-416.
1989
Differences in bone marrow cytogenetic characteristics between treated and untreated myeloma.
Clark, R. E., Geddes, A. D., Whittaker, J. A., & Jacobs, A. (1989). Differences in bone marrow cytogenetic characteristics between treated and untreated myeloma.. European journal of cancer & clinical oncology, 25(12), 1789-1793. doi:10.1016/0277-5379(89)90349-0
Posttransplantation diabetes mellitus in heart transplant recipients.
Ladowski, J. S., Kormos, R. L., Uretsky, B. F., Lee, A., Curran, M., Clark, R., . . . Hardesty, R. L. (1989). Posttransplantation diabetes mellitus in heart transplant recipients.. The Journal of heart transplantation, 8(2), 181-183.
RAS mutations detected by PCR and specific oligonucleotide hybridisation in preleukaemia
Carter, G., Padua, R. A., Hughes, D. C., McCormick, F., Oscier, D., Clark, R. E., . . . Jacobs, A. (1989). RAS mutations detected by PCR and specific oligonucleotide hybridisation in preleukaemia. Cancer Cells, 7, 143-145.
RAS oncogenes
Jacobs, A., Padua, R. A., Carter, G., Hughes, D., Clark, R. E., Oscier, D., . . . McCormick, F. (1989). RAS oncogenes. In D. Spandidos (Ed.), RAS oncogenes (Vol. 170, pp. 1-100). New York: Plenum Press.
1988
13-cis-retinoic acid v placebo in myelodysplasia.
Jacobs, A., & Clark, R. E. (1988). 13-cis-retinoic acid v placebo in myelodysplasia.. Blood, 72(4), 1439-1440.
Myelodysplastic syndrome in a kindred with ins(16) (p11.2).
Clark, R. E., Geddes, D., Whittaker, K., & Jacobs, A. (1988). Myelodysplastic syndrome in a kindred with ins(16) (p11.2).. Clinical genetics, 33(6), 418-423. doi:10.1111/j.1399-0004.1988.tb03474.x
Myelodysplastic syndrome in a kindred with ins(16)(p11.2)
Clark, R. E., Geddes, D., Whittaker, K., & Jacobs, A. (1988). Myelodysplastic syndrome in a kindred with ins(16)(p11.2). Clinical Genetics, 33, 417-422.
1987
Primary myelodysplastic syndrome and cancer.
Clark, R. E., Payne, H. E., Jacobs, A., & West, R. R. (1987). Primary myelodysplastic syndrome and cancer.. British medical journal (Clinical research ed.), 294(6577), 937-938. doi:10.1136/bmj.294.6577.937-a
Effect of 13-cis-retinoic acid on survival of patients with myelodysplastic syndrome.
Clark, R. E., Jacobs, A., Lush, C. J., & Smith, S. A. (1987). Effect of 13-cis-retinoic acid on survival of patients with myelodysplastic syndrome.. Lancet (London, England), 1(8536), 763-765. doi:10.1016/s0140-6736(87)92796-6
A randomized trial of 13-cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome.
Clark, R. E., Ismail, S. A., Jacobs, A., Payne, H., & Smith, S. A. (1987). A randomized trial of 13-cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome.. British journal of haematology, 66(1), 77-83. doi:10.1111/j.1365-2141.1987.tb06893.x
Myeloid surface antigen abnormalities in myelodysplasia: relation to prognosis and modification by 13-cis retinoic acid.
Clark, R. E., Smith, S. A., & Jacobs, A. (1987). Myeloid surface antigen abnormalities in myelodysplasia: relation to prognosis and modification by 13-cis retinoic acid.. Journal of clinical pathology, 40(6), 652-656. doi:10.1136/jcp.40.6.652
The effect of cytosine arabinoside on CFU-GM from patients with myelodysplastic syndrome.
Bailey-Wood, R., Clark, R. E., Dallimore, C. M., & Jacobs, A. (1987). The effect of cytosine arabinoside on CFU-GM from patients with myelodysplastic syndrome.. Clinical and laboratory haematology, 9(1), 23-26. doi:10.1111/j.1365-2257.1987.tb01378.x
1986
Pathogenesis and clinical variations in the myelodysplastic syndromes
Jacobs, A., & Clark, R. E. (1986). Pathogenesis and clinical variations in the myelodysplastic syndromes. Clinics in Haematology, 15, 925-952.
Prognostic importance of hypodiploid hemopoietic precursors in myelodysplastic syndromes.
Clark, R., Peters, S., Hoy, T., Smith, S., Whittaker, K., & Jacobs, A. (1986). Prognostic importance of hypodiploid hemopoietic precursors in myelodysplastic syndromes.. The New England journal of medicine, 314(23), 1472-1475. doi:10.1056/nejm198606053142302
DNA content and cell cycle analysis of bone marrow cells in myelodysplastic syndromes (MDS).
Peters, S. W., Clark, R. E., Hoy, T. G., & Jacobs, A. (1986). DNA content and cell cycle analysis of bone marrow cells in myelodysplastic syndromes (MDS).. British journal of haematology, 62(2), 239-245. doi:10.1111/j.1365-2141.1986.tb02927.x
Pathogenesis and clinical variations in the myelodysplastic syndromes.
Jacobs, A., & Clark, R. E. (1986). Pathogenesis and clinical variations in the myelodysplastic syndromes.. Clinics in haematology, 15(4), 925-951.
1985
Granulocyte and monocyte surface membrane markers in the myelodysplastic syndromes.
Clark, R. E., Hoy, T. G., & Jacobs, A. (1985). Granulocyte and monocyte surface membrane markers in the myelodysplastic syndromes.. Journal of clinical pathology, 38(3), 301-304. doi:10.1136/jcp.38.3.301